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The aim of this study is to investigate the activity of supermolecular iron and ruthenium 
cylinders and their interactions with the DNA replication fork, as the possible target of action 
for cylinders. 
The impacts of two homologues, triple helical iron(II) and ruthenium(II) homologous, as 
metallodrug agents on U2OS cells are studied using different techniques. Both complexes 
demonstrate toxicity with significant IC50 values against U2OS cells, although they improve 
the nongenotoxicity effect in this cell line. These outcomes contrast with the results of 
cisplatin, both in comet and MTT assays. In this study, cisplatin slightly damages the DNA 
helix and does not show significant cytotoxicity against the studied cells. The cellular uptake 
results prove that cells can absorb the ruthenium cylinder, but just one fifth of the total 
ruthenium concentration is detected inside the nucleus, and most is trapped in the membrane.  
Confocal microscopy is applied using two different methods (live- and fixed-cell 
microscopy), to survey the cellular uptake of cylinders in addition to their binding affinity to 
the DNA major groove. Hoechst is used for this purpose, as it is a well-known minor groove 
binder probe. Hoechst decrease in fluorescence as a result of cylinder replacement is not 
observed by these imaging techniques, and the results do not show cylinder interaction with 
the DNA major groove in U2OS cells, despite previous results in other cell lines. Meanwhile, 
the protein immunoblot analysis does not produce desirable results regarding the DNA 
replication fork interaction with the ruthenium cylinder. The P-ChK1 detection results for the 
iron cylinder could not be repeated, despite the fact that in some cases they do demonstrate 
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The magic bullet approach seems to be the appropriate nickname for the cancer therapy 
technique founded by Paul Ehrlich [1] before the dawn of the twentieth century, through 
detection of the specificity of antigen-antibody. He formulated this concept based on the 
affinity of a particular molecule for a certain organ, in order to bring therapeutically active 
groups to the organ to be treated. 
Cancer is the second most common disease, after cardiovascular disorders, responsible for 
human deaths around the globe. [2] Today, battling cancers is considered to be a great hurdle 
and a critical milestone to overcome that directly affects the quality of life in modern 
societies.  
There is a growing list of proposed causes when dealing with the occurrence of cancerous 
malignancies: air pollution, chemical pollution, radiation exposure, and a problematic genetic 
algorithm, to name a few. Different genes that control cell proliferation change during 
mutation, and this disorder can drive cells to divide. Deactivation of tumour-suppressing 
genes and DNA-repairing genes during the mutation is considered to be a cause of abnormal 
cell growth. 
There are various ways to tackle the challenge of cancer treatment, by techniques that can be 
used individually or in combination with one another. Surgery combined with chemotherapy 
and/or radiation therapy are some of the most commonly used methods to cure cancers. 
Moreover, immunotherapy and hormone therapy (classified as targeted therapy methods) can 
be considered as alternative or optional treatment methods. [3,4] 
In chemotherapy, cancer cells are killed by damage to their DNA through the application of 
anticancer drugs. It is important to point out that the type of anticancer drugs used has a 
significant impact on the possible side effects resulting from chemotherapy treatments. For 
example, some of the most common anticancer agents have severe side effects, such as 
anaemia; therefore, much research has been carried out with the purpose of applying the 
targeted drugs in chemotherapy. 
Targeted cancer therapy can be regarded as a brand new and ambitious field of research which 
addresses the design, synthesis and application of particular drugs that target specific genes 
and proteins in each therapy. These drugs can inhibit or block the definite molecules that play 




Targeted therapies are generally cytostatic, in contrast to standard chemotherapies, because 
they target the specific molecules associated with cancer. [5, 6] 
In recent years, many anticancer drugs have been studied for use in smart therapy. Metal 
complexes with remarkable properties and special abilities to connect with critical 
biomolecules are known to be effective drugs in these new cancer therapy methods. Inorganic 
medicinal chemistry has flourished after the discovery of cis-dichlorodiammine-platinum(II) 
(cisplatin). The pioneering discovery of this anticancer drug with outstanding anticancer 
properties has pushed the frontiers of conventional cancer therapy. Cisplatin, as one of the 
most famous anticancers, has been used in treating a vast range of cancer cell lines. However, 
this small metallodrug also exhibits some dramatic side effects. In addition, some cancers are 
resistant to cisplatin. These major disadvantages of this platinum-based anticancer have led to 
the investigation in this thesis of the design and synthesis of new and effective non platinum-
based metallodrugs, in order to achieve the targeted therapy without the harmful side effects. 
[7] 
A large number of biomolecules, such as peptides, proteins, DNA, RNA and small molecules, 
can be targeted by metallodrugs in biological systems. As a carrier of all human genetic 
information in all cell types, DNA is undoubtedly known as the best target for metallodrugs in 
cancer therapy. It is evident that targeting the DNA of cancerous cells can activate the system 
of cell apoptosis in tumours without damaging the normal cells, and these kinds of smart 
therapies have recently been successfully studied with metal complexes. 
This study examines the synthesis methods of two iron and ruthenium cylinders as special 
metallodrugs, and surveys their modes of DNA binding (specifically on the DNA replication 
fork) and cytotoxicity in human bone osteosarcoma epithelial cells (U2OS).  
Chapter one summarises the theoretical background of this investigation, and includes 
reviews of the DNA molecular structure, its modes of interaction with various metallodrugs, 
and the reasons behind their anticancer characteristics being affected by DNA binding modes. 
The diversity of metal complexes is then explored, particularly iron and ruthenium 
complexes, with a survey of their biological and antitumour properties. The study specifically 
focuses on iron and ruthenium cylinders, and explores their interaction modes with biological 




Chapter two describes the experimental procedure, including the synthesis and purification of 
iron and ruthenium cylinders and U2OS cells cultured. It also surveys the toxicity of both 
cylinders against U2OS cells by MTT assay. The damage to DNA by cylinders is investigated 
and explained by comet assay. Moreover, cell uptakes are checked with ICP-MS, and the 
modes of cylinders’ interactions with DNA are studied by imaging microscopy using both 
live- and fixed-cell techniques, followed by the western blot method.  
Chapter three comprises results and discussion pertaining to each experiment. For each test, 
the results section explains the hypothesis behind the test, the expected data and the exact 
results. This is followed by a logically supported discussion of the results in relation to the 



























































The anticancer metallodrugs are known to be effective tools that target intracellular 
biomolecules such as DNA, RNA and proteins. As a vital part of the cellular genome, DNA 
and its possible modes of interaction with metallodrugs has been widely studied. Various 
types of metal complex drugs, their effects on cancerous cells and their modes of binding with 
DNA or other cellular molecules are discussed extensively in this chapter.  
 
1.2 2′-Deoxyribonucleic acid (DNA) 
Deoxyribonucleic acid (DNA) is the fundamental biomolecular structure that carries the 
genetic codes of organisms. This long polymeric biomolecule was discovered by Friedrich 
Miesche at the University of Tübingen in 1869. [8] Nucleotides are the subunits of DNA. The 
Nucleotides are composed of a nitrogenous base (Fig. 1.2), a five-carbon sugar which has 
bonded with the heterocyclic base such as cytosine (C), guanine (G), adenine (A) or thymine 
(T) (Fig. 1.1). A phosphodiester can link the 5’-end of one sugar to the 3’-end of the other, 
and nucleic acid sequences are written in the 5' to 3' direction. Adenine and guanine are 
purines, while cytosine and thymine have a pyrimidine structure. [9] 
 
 





Fig. 1.2. The structure of purine and pyridine heterocyclic ring systems. Taken from ref 200.
 
 
The building blocks of DNA consist of a phosphate base on the 5′-carbon position, with the 





Fig. 1.3. The structure of deoxynucleotides. Taken from ref 200.
 
 
The molar amount of adenine in DNA has been found to always be equal to that of thymine; 
the same is also true for guanine and cytosine. [10,11] Consequently, the rule of nucleotide 
junctions between two different strands demonstrates that the linkage of adenine (A)–thymine 
(T) and guanine (G)–cytosine (C) is possible. These complementary DNA bases are 
connected to each other through hydrogen binding (Fig. 1.5). [9] 
 
 
Fig. 1.4. The DNA double helical structure with structural elements indicated. Both major and minor 













In a eukaryotic cell, the DNA molecule is a double-strand biopolymer consisting of 
nucleotides coiled around each other to form a double helix; this form was discovered by 
Watson and Crick in 1953. [9] Since each nucleotide is able to form a hydrogen bond with a 
specific nucleotide (see Fig. 1.4), the sequence of a single strand of DNA also defines the 
parallel sequence. As a result, each strand has the reverse structure of its parallel strand, with 
the 5′-end of one strand placed adjacently to the 3′-end of the other. It is noteworthy that π-π 
interactions are present in DNA’s double helix among the stacked aromatic rings of 
longitudinal bases on the polynucleotide chains, thus providing the stability of the DNA helix. 
The DNA backbone strands remain situated close together because of the hydrogen bonding 
present between them. The DNA structure can be divided into two groove parts, termed the 
major and minor grooves, which curl around the molecule on opposite sides. This 
classification is based on the distance between the backbones; in the case of major grooves 
this distance is greater, while for minor grooves the situation is reversed (Fig. 1.6). [13] 
A right-handed double helix is formed in the case where two strands turn around each other, 
and the backbone facing the observer moves in a downwards sense from the top right to 
bottom left. In this structure, the external hydrophilic backbone is shaped by the hydrophobic 












Fig. 1.7 Three-dimensional structures of A, B (right-handed) and Z (left-handed) DNA structures. Taken from 
ref 202. 
 
The symmetrical grooves in double-stranded DNA are formed when the glycosidic bonds 
protrude at a 90-degree angle on both sides. [14] The role of glycosidic bonds is to attach the 
nucleic base to the sugar in the backbone, and the presence of an angle between the glycosidic 
bonds and the interface between the AT or GC pairs results in one of the faces of the base pair 
being larger than the other. [9,14] The basic proteins with the responsibility of DNA 
replication, transcription or modification are, in principle, bound to the major groove rather 
than the minor one. As a result of the position of DNA backbones and the wide angle, it is 
easier for the proteins to bind with the major groove sides.  
As shown in Figure 1.8 there are three basic conformations of DNA helices: A-DNA, B-DNA 
and Z-DNA. [15] 
Studies on the crystal form of oligonucleotide duplexes have confirmed that there are 
significant differences between the different DNA conformation structures in some basic 






Table 1.1. The average parameters of the three DNA conformations. Taken from ref 15. 
 
Structural parameter A-DNA B-DNA Z-DNA 
Direction of helix Right rotation Right-handed Left-handed 
Residue per helical turn 11 10.5 12 
Axial rise per residue 2.55 Å 3.4 Å  3.7 Å 
Pitch (length) of the helix 28.2 Å 34 Å 44.4 Å 
Base pair tilt 20° -6° 7° 
Rotation per residue 32.7° 34.3° -30° 
Diameter of helix 23 Å 20 Å 18 Å 
Configuration dA, dT, dC anti  anti anti 
of glycosidic bond dG anti anti syn 
Sugar pucker dA, dT, dC  C3' endo C2' endo C2' endo 
 
The most common form of DNA is B-DNA, that is, the canonical right-handed DNA helix. 
Standard B-DNA comprises two antiparallel double helix strands. [15] This DNA 
conformation type has a wide major groove, making it suitable for binding with proteins that 
interact with the DNA. Furthermore, its narrow minor groove is a good target for small drug 
molecules to bind with DNA, such as distamycin. [16] 
The A-form nucleic acid is a thicker right-handed DNA duplex with a shorter distance 
between its base pairs. A-form and B-form nucleic acids are particularly determined on the 
basis of the order of their base pairs inside the duplex: the B-form is characterised by the 
base-pairs being rather centred over the helical axis, while in the A-form the base pairs are 
closer to the major groove, which produces a ribbon-like helix with an open cylindrical core. 
[199] 
The Z-DNA conformation, with its ‘zig-zag’ appearance, is fundamentally different to the 
other two forms of the duplex (Fig. 1.8). This structure comprises a strand coiling in a left-
handed helix with the repetition of dinucleotide units. Furthermore, Z-DNA consists of an 
alternating purine-pyrimidine sequence (dCGCGCG); the zig-zag pattern results from the 










Generally, the vast majority of DNA double helices in eukaryote cells possess the B-form of a 
duplex in their genetic codes, while Z-DNA can only be found in some living cells. [18,19,20] 
 
1.3 Modes of DNA interaction 
In pharmacology, DNA is the most important target for anticancer metallodrugs to control 
gene expression. These drugs include transition metal compounds containing Ru, Co, Ni, Cu, 
Zn, Fe and other rare-earth compounds. [23] 
There are several known mechanisms for the interaction between metallodrugs and DNA that 
have been discovered since the 1960s. [21,22] Considering the many possible binding sites on 
DNA that result from the varying electrochemical properties, size and complexity of 
nucleobases, two binding interaction modes can be demonstrated: irreversible, such as 
covalent binding, and reversible, such as intermolecular association. The main modes of DNA 
binding are classified as alkylation or covalent binding, groove binding (both major and minor 
forms), intercalation, and unique binding modes such as Y-junction, cruciform and hairpin, 
and G-quadruplex. [57] 
1.3.1 Alkylation or covalent binding 
Covalent binding is known as a common form of anticancer drug interaction with DNA. In 
general, covalent bonds are formed by strong electrophilic compounds that undergo chemical 
reaction with nucleophilic sites on the DNA structure. Alkylating agents can produce an 
irreversible bond with DNA nucleotides, consequently inhibiting the processes of 
transcription or replication and leading to cell death. [230] 
The N(7) atom of guanine and N(3) atom of adenine are two active sites at the DNA base that 
react to alkylators. Nucleophilic substitution reactions can occur by both SN1 and SN2 




busulphan and their analogues) react by an SN2 mechanism, while nitrogen mustard can 
cause the aziridinium ion to proceed to the SN1 mechanism (Fig. 1.9). [24] 
 
 




Cisplatin (cis‐ [PtCl2(NH3)2]) is a famous anticancer metallodrug that is used to cure various 
types of cancer, such as ovarian and cervical cancer and melanomas, and is especially well-
known for its use in curing over 90% of testicular cancers. Cisplatin is able to affect DNA by 
forming a strong coordination bond with nitrogen 7 of guanine and adenine in the DNA 
backbone (Fig. 1.10). [25,26]  
 
 






Published studies also illustrate the reaction of this compound with a vast range of 
biomolecules in various kinds of cells. [27] Furthermore, cisplatin (generally the clinical 
DNA covalent binder) as an metallo-organic drug has also shown good results in treating 
diseases other than cancers.  
Other cisplatin analogues with a similar mode of interaction with DNA have been synthesised 
in recent decades, including carboplatin, heptaplatin and oxaliplatin. [27] These compounds 
were designed to avoid the negative side effects of cisplatin in cancer therapies (Fig. 1.11). 
 
 
Fig. 1.11. The structures of three derivatives of cisplatin. Taken from ref 196.
 
 
Other non-platinum(II)–DNA covalent binders have also been designed in recent years. For 
instance, the titanium complex budotitane ([Ti(bzac)2(OEt)2] is one such well-known 
metallodrug with a very powerful anticancer property. Titanocene dichloride has also passed 
clinical trials. Hypothetically, this compound forms a covalent bond with DNA and is highly 








1.3.2 Groove binding 
DNA binding drugs generally act through one of the grooves of DNA, depending on their size 
and shape. Reversible electrostatic binding can occur by way of interaction between the 
positive sites of drugs and the negative sites of the phosphate backbone of the DNA helix. As 
a result of the fact that the major and minor grooves have different dimensions, to target them 
requires molecules with very diverse shapes. [32,33] 
The difference in the dimensions of the two grooves is the reason for their differing 
interactions with various molecules. The width of the major groove is normally about 5.6 Å 
greater than that of the minor groove for the B-form ds-DNA sequence. [34] 
1.3.2.1 Minor groove binders  
The dimensions of the minor groove make it suitable for binding with small molecules, such 
as antibiotics; accordingly, this subject has become a research topic of high demand for 
scientists. In addition, the high binding affinity of the minor groove and its sequence 
specificity make it a more interesting mode of interaction than that of the intercalator binding 
mode. [221] 
Minor groove binders are small molecules with a specific heterocyclic size and shape that can 
rotate freely. This property allows them to fit easily into the minor groove by the 
displacement of water. These molecules are useful in different areas of pharmacology, such as 
antiprotozoal, antiviral, antibacterial and antitumour. Although minor groove binder drugs are 
considered as an important class of antitumours in cancer therapy, only some are able to work 
as active anticancer agents in the body and to achieve good results in clinical therapy. [35] 
Depending on their structure and potential sites, they are categorised into two different classes 
having either irreversible or reversible binds with DNA: the former class includes mitomycin 
C, anthramycin, CC-1065 and its synthetic analogues (carzelesin and adozelesin), enediyne 
antibiotics (neocarzinostatin, esperamicin A1 and calicheamicin g1), ecteinascidine derivative 
(ET-743) and bleomycin. These molecules cause permanent damage on DNA through 
irreversible binding with DNA nucleotides. The latter class includes distamycin A, 
diarylamines (DAPI, Berenil, and pentamidine), and bis-benzimidazoles such as Hoechst 
33258. This group produces a reversible inhibition on DNA, and most of these compounds 
interact with AT-rich regions of DNA. [36,37] 





carboxamid]propionamidin-hydrochlorid), is a natural pyrrole-amidine-antibiotic that 
possesses amino groups and three pyrrole rings, which can form a hydrogen bond with AT-
rich regions of DNA as well as hydrophobic interactions. The terminal amidine group of the 
small molecule is basic and serves to attract the drug molecule to the negatively charged DNA 
phosphodiester backbone. The 2-amino group of guanine prevents distamycin from binding to 
the minor groove of GC base pairs by steric hindrance, thus conferring AT-selectivity on the 
drug molecule. In this way, distamycin inhibits transcription and increases the activity 
of topoisomerase II. Netropsin, another analogue of distamycin, has two N-methylpyrrole 
rings and demonstrates the same activities (Fig. 1.12). [38,39] 
 
 
Fig. 1.12. DNA minor groove binding in oligopeptide netropsin (above) and distamycin (below). Taken from 
ref 204. 
 
To increase DNA binding and the sequence selectivity of drugs, the semi-synthetic compound 
lexitropsin was synthesised as an analogue of distamycin and netropsin, to promote the 
relevant between similar units in the ligand and receptor. These polyamide molecules are 
designed to recognise the base sequence of DNA. The structure of lexitropsin, with three 
types of pyrrole units, imidazole and hydroxypyrrole give the full distinction of specific DNA 






Fig. 1.13. Schematic representation of the interaction between lexitropsin and the AT-rich side of DNA. 
Taken from ref 38. 
 
The di-nuclear zinc complex linked with azobenzene chromophore ligands, [Zn{meso-
tetrakis-(N-methyl-4-pyridyl)porphine}]
4+
, shows an affinity to the association in the DNA 
minor groove. The complex has been found to be self-associated between DNA minor groove 
strands and can cleave the DNA strands hydrolytically. This complex has two cis and trans 
isomers, which can be transformed into each other by photoisomerisation. However, only the 












   
(b) 
Fig. 1.14. a) The chemical structure of [Zn{meso-tetrakis-(N-methyl-4-pyridyl)porphine}]4+, the DNA 
groove binder; b) di-nuclear cis isomer of cationic porphyrins with different linkage factors represented (R). 
Taken from ref 215. 
 
1.3.2.2 Major groove binders  
While various metallodrugs that are minor groove binders have been studied during recent 
decades, limited reports exist of major groove binders in this category. Due to the fact that the 
major groove is wider than the minor groove, they are suitable for binding by DNA-protein 
interaction. On average, the major grooves represent 11.6 and 6.0 Å in B-form ds-DNA; this 
size is desirable for binding with small biomolecules such as proteins. [51] Therefore, the 
design of a special molecule with the ability to recognise the major groove of DNA with high 




be blocked by inhibiting the proteins binding with the major grooves of DNA, as a result of 
using major groove binder molecules. [51]   
Metal-supramolecular compounds, depending on their size diversity, shape, the potential 
polarisability of their ligands and capability to form hydrogen bonds, can target the major 
groove differently. Transition metal complexes are known as interesting compounds with 
remarkable properties in terms of binding with DNA. Some examples include their varied 
coordination capacity to create a complex with different spatial geometry, various adjustable 
redox states to exhibit positive charges, and a vast range of other properties that make these 
compounds suitable for interaction with the DNA double helix in different modes. Because of 
their ability to utilise different binding modes to DNA (such as covalent and noncovalent 
binding), as well as their capacity for inducing DNA strand scission, these complexes can be 
applied as DNA probes and anticancer drugs. [32] 
In recent decades, metal complexes have been considered because of their various 
possibilities, and have
 
to be chosen from the list of transition metals (e.g. Rh, Ru, Os, Re, Pt, 
Cu, Co, Fe, Mn, and so on); in addition, various kinds of ligands can be investigated as photo 
nucleases. The properties of these ligands, such as their low energy and ability to form 
electronic bands in the visible region, are considered to be essential characteristics for 
metallodrug complex therapies. [32] For instance, rhodium complexes have been studied due 
to their DNA cleavage abilities; Rh(II) complexes containing polypyridyl aromatic ligands, 
[Rh(phen)2(phi)]3+, were designed and studied by Chow and Barton in 1992
 
as an anti 
double-strand DNA agent (Fig. 1.16). [51]
 
This complex represents the ability to bind with the 
DNA helix in various modes according to its special stereochemistry, together with the 
properties of the aromatic ligands in a complex structure. It is important to note that this 
complex bind with the major groove by forming hydrogen bonds bond between the 9,10-
phenanthrenequinone diimine (phi) groups of ligands with B-DNA, and with the hydrogen 







Fig. 1.16. The structure of Rh(phen)2phi3+, which targets openings in the DNA major groove. Taken from ref 
51. 
 
Copper complexes are mostly known as extensively studied examples of major groove binder 
compounds. The [Cu(ferrocenylmethylbis(2-pyridylmethylamine)(dppz)](ClO4) complex 
with two different ligands, ferrocenylmethylbis(2-pyridylmethylamine) and the dppz bind to 
the major groove of DNA, and exhibit photo-induced DNA cleavage properties under the 
light. (Fig. 1.18). [51] The results of photodynamic therapy (PDT) show that the complex 
shows DNA photo-cleavage under both visible (458 and 568 nm wavelengths) and red 





Fig. 1.17. Structure of the photo-interaction of [Cu(L)(dppz)](ClO4)2 complex with the DNA major groove. 
Taken from ref 46. 
 
The diversity in the stereochemistry and physical properties of ligands in ruthenium(II) 
polypyridyl complexes are the reason why they are able to bind directly with both the major 
and minor grooves of DNA. [57] Research has shown that the major grooves of DNA are 
mostly occupied by compounds having a large size and adequate intercalation elements. One 
example of a ruthenium(II) complex is Λ-[Ru(3,4,7,8-tetramethyl-1,10-phenanthroline)3]
2+
 











groove binder. Taken from ref 54. 
 
The P and M isomers of the supramolecular iron complex [Fe2(L)3]
4+
 (where L represents [μ-
[4,4′-methylenebis[N-[(2-pyridinyl- κN)methylene]benzenamine-κN]]]) illustrates that the M 
enantiomer of the iron cylinder bonds with the major groove of DNA, and can induce 
dramatic intramolecular coiling. In contrast, the P enantiomer is unable to induce coiling, but 




Fig. 1.19. Schematic representation of intramolecular DNA coiling induced by an iron triple helical cylinder. 
The picture demonstrates the AFM images of free linear plasmid DNA (on the left side of the picture) and the 
impact of the cylinder on linear DNA to make a small unexpected DNA coil (on the right side of the picture). 
Taken from ref 206. 
 
The dinuclear ruthenium complexes [Ru2(1,10-phen)4L1]4+ and [Ru2(bpy)4L1]4+, where L1 
represents (C5H4N)C=N(C6H4))2CH2), show a selective groove binding affinity when used 
in an enantiomerically pure form. [58] However, both phen complexes exhibit different 
activity when binding with DNA. The GC-rich sequence of DNA is the site of Δ, Δ-
[Ru2(phen)4L1]
4+
 interaction, and the AT-rich sequence is the target of another enantiomer. 






The insertion of aromatic heterocyclic compounds (which are mostly flat, positively charged 
and planar) in between the base pairs of DNA’s right-handed helix is called intercalation. 
After Lerman in 1961 [59], an extensive range of organic and inorganic chemical compounds 
have been designed as intercalator anticancer agents. In general, DNA intercalator agents act 
as anticancers by destroying the DNA transcription process and blocking cell division, leading 
to cell death. The π–π stacking interactions between DNA base pairs and the aromatic rings in 
drug structures are the factors that stabilise the insertion of the intercalator agents. Moreover, 
the combination of other types of interactions, such as van der Waals, hydrogen bonding and 
hydrophobic interactions, also plays a significant role in insertion stabilisation. [60] DNA 
unwinding takes place when the intercalator agents open a gap between the stacked base pair, 
which can occur in either major or minor grooves. Many metallo-intercalators as anticancers 
have been designed during recent years. It is important to note that these compounds 
commonly include anthracenes, phenanthrolines, acridines, anthraquinones, ellipticines and 




Fig. 1.20. The structure of various metallo-intercalator ligands. Taken from ref 207. 
 
Notably, the aromatic ring systems play a significant role in modes of DNA interaction (see 











Fig. 1.22. Ligands with different aromatic ring systems represent different DNA modes of interaction. Taken 
from ref 64. 
 
The first noncovalent DNA binding drug that has been widely used in cancer therapy is 
metallobleomycin. [62] This compound is part of the class of glycopeptide antibiotics, which 
was found in 1960. [62] A variety of metals, such as Cu(II), Zn(II) and Co(III), have been 
used as the central metal in the metallobleomycin structure, which forms an octahedral 
complex. Two octahedral forms and the positively charged tail of the complex are the reasons 






Fig. 1.23. A schematic representation of the bleomycin structure. Taken from ref 208. 
 
One of the most important classes of metalloanticancers drugs are platinum complexes, which 
have displayed remarkable anticancer properties. The [Pt(phen)(en)]
2+
complex with the 
general formula of [Pt(IL)(AL)]
2+ 
consists of two ligand parts: IL as an intercalating factor, 
and AL as a non-intercalating ancillary item. This complex generates DNA length and 
stiffness by intercalating into the DNA minor groove, particularly between the C3–G4 and 
T2–A5 base pairs (Fig. 1.24). [63–65] 
 
Fig. 1.24. The structure of [Pt(phen)(en)]
2+
complex, and the molecular simulation of the complex intercalated 
with the DNA sequence d(GTTGCAAC)2. Taken from ref 74,53. 
 
The complex ligands play a significant role in complex biological activity, such as DNA 
affinity. For example, the positive charge of the complex causes the activation of both cellular 
uptake and DNA affinity. [66]   
Octahedral ruthenium(II) complexes are known as effective anticancer active compounds, and 






 with two optical isomers (Λ/Δ) has shown significant biological activity 
against cancer cells (Fig. 1.25). Studies show that both chiral enantiomers function differently 
in cells, due to their optical properties. Furthermore, their spectral properties (i.e. their 
fluorescent properties) is dramatically increased after forming a bond to DNA, which makes 
them very attractive for application as DNA fluorescent probes. [67,68]   
 
 
Fig. 1.25. The structures of two optical isomers (Λ/Δ) of [Ru(phen)3]2+. Taken from ref 208. 
 
The type of metal in the metallo-intercalator compound plays an important role in its relative 
biological activity in terms of its binding affinity to DNA. Complexes of copper, zinc and 
nickel with the N4-tetradentate ligand, such as [M(N,N’-bis-5-(triethylammoniummethyl)-
salicylidene-2,3-naphthalendiiminato)]n+, represent intercalating insertion with differing 
DNA binding affinity. When comparing the abovementioned metal complexes such as Ni, Zn, 
and Cu, it is evident that their spherical geometry is the key factor in their DNA affinity and 
insertion. As an example, square planar shapes, such as Ni complexes, are able to insert more 
deeply between DNA base pairs than octahedral shapes, such as Zn and Cu complexes. 
Copper complexes of phen and its derivatives have shown significant results in cancer 
treatment and as antibiotics. When an activating compound is present, DNA cleavage can 
occur by oxidising agents generated by the DNA-copper complex in cells. [69] For example, 




parts, which formed effective bonds with the serinol bridge, caused considerable DNA 
cleavage in studied cells (Fig. 1.26). [70–72]   
 
  
Fig. 1.26. The structures of two copper DNA intercalators: a) [Cu(3-clip-phen)]2+, and b) [Cu(2-clip-
phen)]2+. Taken from ref 73. 
 
A lot of research has been done on rhodium complexes that represent good results in cancer 
therapy based on their high selectivity on DNA sequences to linking and their ability of 
nuclease-cleaving. For an example the octahedral rhodium complex: Δ-[Rh(phi)(R,R-
Me2trien)]3+ (where phi is 9,10-phenanthrenequinone diimine and R,R-Me2trien - 2R,9R-
2,9-diamino-4,7-diazadecane) intercalates between GC base pairs of the DNA major groove 
by forming hydrogen bonds between the guanine parts and amine groups of the phi ligand 
(Fig. 1.27). [73]    
 
Fig. 1.27. The structure of Δ-[Rh(phi)(R,R-Me2trien)]3+. Taken from ref 73. 
 
1.3.4 Y-junctions 
Three-way junctions (3WJ), are not the simplest and most commonly occurring branched 





Huntington’s disease. They have a special structure with three double helical arms, A, B and 
C, which are connected to one another at the junction point. This consists of some unpaired 
bases in at least one of the junction’s hands. When one strand in a major groove (termed the 
third strand) forms a bond with the DNA double strand, the 3WJ is formed; an acidic pH is 
necessary at this point. [74] Y-junctions represent a lack of stability compared to DNA double 
helix strands, so they are suitable targets for metallodrugs to stall the DNA fork at a higher 
ratio than DNA duplexes. For instance, Hannon designed an iron cylinder with the 
formulation [Fe2{μ-[4,4′-methylenebis[N-[(2-pyridinyl-κN)methylene]benzenamine-κN]]}3] 
which flawlessly fits into the central cavity of the Y-junction structure. The iron cylinder can 
also block the centre of a 3WJ in RNA (Fig. 1.28). [75] 
 
 
(a) (b) (c) 
Fig. 1.28. a) The crystal structure of the cylinder’s 3WJ interaction in RNA; space-filling models of the 3WJ 
blocked with a cylinder (shown in green) in: b) RNA and c) DNA. Taken from ref 74. 
 
1.3.5 G-quadruplexes 
G-quadruplex DNA or QDNA structures are forms of DNA and are rarely found in the 
telomeres and believed to be formed transiently in the promoter regions of genes in the human 
genome. G-quadruplexes are generated by self-assembly in Hoogsteen fashion, and consist of 
the basic G-quartet unit (four guanines of base pairs bonded together). Notably, metal ions 










Fig. 1.29. a) Scheme of a G-quartet and the form of an intermolecular G-quadruplex structure; b) various 
representations of G-quadruplex arrangements, both intermolecularly and intramolecularly. Taken from ref 
73. 
 
The G-quadruplex form of DNA is a structure that can stall the terminal transferase or 
telomerase enzyme if the formation of QDNA occurs at the 3′ end of the telomeric DNA. [76] 
The stabilisation of this structure is therefore a significant factor in cancer therapies. As 
mentioned above, metal ions play a key role in structure stability. Studies confirm that alkali 




 can stabilise this structure by forming coordinated bonds with 





Fig. 1.30. Coordination bonds between oxygen atoms, hydrogen atoms and an alkali metal in the centre of the 
G-quartet channel, which improve the stability of the structure. Taken from ref 77. 
 
Importantly, the activity of telomeric DNA of cancer cells, meaning that terminal transferase 
activity in cancer cells is high and reaches about 85%; however, it is silent in normal human 
cells. [79,80] The activity of telomerase guarantees maintaining the DNA of telomeric cancer 
cells. Moreover, DNA transcription is blocked when the G4 structure is formed in G-rich 
single strands. Thus, the inhibition of this enzyme and DNA transcription with the G-quartet 
structure key roles in cancer therapy. Small molecule ligands in the structure of anticancer 
drugs can interact, stabilise or selectively cleave the hTel G4 structure or its promoter, in 
order to treat the targeted cancer cells (without the side effects caused by drug toxicity in 
normal cells). [81]   
However, cisplatin as a famous anticancer is classified as a small metallodrug that can interact 
with the G4 structure and cause cell apoptosis. Cisplatin is not a targeted selective drug, and 
causes severe side effects due to its interaction with various biomolecules in cells besides the 
G-quartet structure. Many investigations of metallodrugs targeting the G4 structure have been 
initiated recently. For example, a variety of ligands have been used in the structures of drug 
complexes, such as metallophthalocyanines, metallocorroles, metal–salphen, metal–salen, 
metal–phenanthroline and their derivatives. [82]   
The Au III in metalloporphyrin complexes, gold(III)–TMPyP4 (Fig. 1.31), is one compound 
that has shown good results in stabilising hTel G4, and is also known as a strong telomerase 




by blocking the PCR (Polymerase chain reaction )amplification of a G4 sequence. The 
toxicity of this anticancer in normal nasopharyngeal cells is IC50 > 50 μM. [82]   
 
                               (a)                             (b) 
Fig. 1.31. a) A scheme of the total structure of metal-TMPyP4 as kinds of G-quartet ligands; b) the structure 
of gold(III)–TMPyP4 complex. aken from ref 81. 
 
Meso-methylpyridinium-substituted Mn(III)–corrole, as a type of metallocorrole complex, has 
a high toxicity in cancer cells, with values of 2.37 and 1.52 μM. This water-soluble complex 
can stabilise hTel and c-myc G-quadruplex DNA with the desired shape and electron 
concentration (Fig. 1.32). [73–85]   
 
 




Cylinders are a new class of G4-targeted chiral binders. Their properties have been recently 
studied as anticancers in biological systems; for example, the ability of selective QDNA 






Fig. 1.33. a) Structures of the M-enantiomer (left) and P-enantiomer (right) of the [Ni2L3]4+ cation; b) 
structures of the M-enantiomer (left) and P-enantiomer (right) of the [Fe2L3]4+ cation. Taken from ref 209. 
 
While both cylinders can stabilise hTel G4 DNA or telomeric QDNA, the P-enantiomer is 
more active in binding with the G4 structure. The cell can be protected from the endonuclease 
enzyme when the cylinder forms bonds with hTel G4, as a result of the electrostatic 
interaction generated by the metal’s positive ion charge in the cylinder structure (Fig. 1.34). 
[86]   
 
Fig. 1.34. The selective recognition of the supermolecular cylinder of telomeric G-quadruplex DNA. Taken 
from ref 209. 
1.4 Metal complexes and their therapeutic effects 
For centuries, metals have had medical applications. [57] More recently, modern metallodrugs 
have also demonstrated excellent results in treating various kinds of diseases, such as cancers. 




to survey their effects on targeted live cells and tissues; and b) by in vivo study with xenograft 
tumour models. 
Organometallic compounds, which are the combination of classic inorganic compounds with 
organic ligands, have thus become a new field of research in chemistry. 
One of the most extensively researched topics is metallodrugs, which aim to bind to DNA in a 
non-coordinative manner. This is because noncovalent DNA interactions with various 
functions have been already seen in nature. [87] 
 
Metal complexes are known as compounds with high potential to engage in interactions with 
different biological targets in vivo. Metallodrugs can form different kinds of interactions with 
intracellular targets, such as irreversible (covalent) and reversible (noncovalent) bindings. For 
instance, titanocene dichloride [Ti(CP)2(Cl)2] is known as one of the most famous anticancer 
drugs has successfully passed its clinical trial. This complex can form covalent binding to 
DNA. [88,89] Although the square planar structure of titanocene is similar to that of cisplatin, 
the hydrolysis of halide ligands within this complex (in order to bind to DNA) happens 
outside the cells. Accordingly, a multinuclear complex can be formed as an active product. 
[90]  
 
Two zinc and cobalt complexes can interact with DNA (by noncovalent binding) through 
associations inside the DNA groove. For example, cis-[Co(en)2(bpy)2]
+3
 exhibits toxicity in 
cancer cells with separation in DNA strands after association within the minor groove. [71,72]  
 
Because copper and zinc are naturally present in the human body and have a critical influence 
upon cellular functions, they have been extensively used as DNA nucleases in medicinal 
chemistry. [93]   
The zinc complex [Zn(L)2]2+, L is 2,6-bis(1-phenyl-1H-benzo[d]imidazol-2yl)pyridine 
(bpbp) (Fig. 1.35) was recently reported. This complex shows high toxicity against various 
cell lines, such as the IC50 2.9 -0.3 µM value in MCF-7 cells. It’s important to note that the 
p53 gene, which is activated in response to any intracellular stresses such as DNA damage, 
can induce cell apoptosis. In this case, the activation of the p53 gene following DNA cleavage 
generated by intercalation of [Zn(L)2]
2+
 complex through the DNA structure can thus 






Fig. 1.35. The structure of the [Zn(bpbp)2]
2+
complex. Taken from ref 73. 
 
The natural bioavailability of copper, in addition to its role in angiogenesis and increased 
uptake in cancerous tissues, has resulted in its wide range of applications in medicinal 
inorganic chemistry, and more specifically in antibacterial and anticancer agents for many 
years. [96,97] There are some properties that make copper complexes suitable as important 
anticancer agents. As it has a variety of different coordination numbers, copper is able to form 
complexes with various geometries that can interact with similar molecules in different 
manners. [100,102] Moreover, the intercalation of copper complexes through the DNA 
structure with the ability of DNA cleavage (independent of oxidising agents) plays a critical 
role in DNA damage and cell death. [100,101]  
While there are a variety of copper complexes with the capability of anticancer activities, its 
phenanthroline complexes have shown low-micromolar activity against many different cancer 
cells, such as SKOV3. Figure 1.36 presents the structure of phenanthroline copper complexes 
and the possibility of its different ligands. [214]   
 
 




1.4.1 Platinum-based anticancers 
One of the most famous metal anticancer drugs that has been sold to treat various kinds of 
cancers is cisplatin, the so-called ‘DNA paradigm’. The discovery of cisplatin by Rosenberg 
et al. in 1965 laid the foundation for the current developments in organometallic drugs as 
anticancers. [104] Cisplatin can show great results in curing various kinds of cancers, 
specifically testicular cancer (with a 90% cure rate). [105] Over time, this compound has 
represented successful clinical treatment, thus making it the first popular platinum anticancer 
drug. 
In recent years, other platinum complexes have been introduced to the pharmaceutical market 
as new targeted cancer therapy medicines, such as carboplatin, lobaplatin, oxaliplatin and 
nedaplatin. These compounds are used in 50% of all cancer chemotherapies. 
Cisplatin analogues can bind to DNA and stop the replication process, and thus the cause of 
cell death. [106,107] Although cisplatin and its analogues react with various parts of cells’ 
biomolecules, DNA remains an important target. [108,109]   
 
1.4.1.1 DNA as a target of cisplatin 
Research has shown that uptaking cisplatin through cells occurs by a passive diffusion 
process, or sometimes by active transportation. In addition, cisplatin’s labile chloride ligands 
are a cause of cisplatin–DNA binding in cells (Fig. 1.37). Normally, neutral cisplatin 
molecules undergo hydrolysis inside cells due to the fact that cells have a very low 
concentration of chloride ions (2–20 mM), in spite of the high concentration of chloride ions 
(100 mM) in arteries. Replacing chloride ions with water can generate the positive charge 
needed for cisplatin to facilitate favourable interactions with polyanionic nucleic acids. [110] 
The [Pt(NH3)2Cl(OH2)]
+ 
complex is formed during this process and plays a significant role 
in forming a bond with DNA, mostly with certain nitrogen atoms of purine bases in DNA at 
the N
7
 position. These free positions of nitrogen do not bind to other DNA bases, so they are 
free to form a bond with cisplatin. Accordingly, the DNA double helix is opened and the 
transcription process is subsequently inhibited. The failure of DNA transcription activates 
proteins in the network of intracellular signals called DNA damage response, in order to 







Fig. 1.37. The intracellular hydrolysis mechanism of cisplatin. Taken from ref 111. 
 
As shown in Figure 1.39, cisplatin can impact on cancerous cells in several ways: by targeting 
DNA, RNA, mitochondria, sulphur-containing enzymes such as metallothionein nucleotide 




Fig. 1.39. A scheme of cisplatin hydrolysis inside the treated cell and its three possible apoptotic pathways 
through targeting DNA, RNA, and mitochondria.  
 
The toxicity of cisplatin arises from crosslinking cellular DNA, which can repress DNA 




important characteristic that has an impact on its anticancer activities. 
Diamminedichloroplatinum has two cis and trans geometric isomers; unwinding of the helix 
occurs when the cis configuration forms intra-strand crosslinks with DNA, causing 
transcription to stall and consequently cell apoptosis. Transplatin (the trans isomer) degrades 
quickly in vivo and does not work as an anticancer. Because of the separate strand 
crosslinking (1,2-interastrand and 1,3-interastrand) performed by transplatin, it can be 
repaired easily, in contrast to cisplatin (Fig.1.40). [113] Moreover, the square planar form of a 
platinum(II) complex helps to better bind with DNA strands, and Cl- substitution in a 
complex with the nitrogen of the DNA base occurs more easily in cisplatin than in transplatin. 
[114, 115] The bond formed between DNA and cisplatin is irreversible. 
 
 
Fig. 1.40. A schematic representation of the difference between cisplatin and transplatin in binding with 
guanine-7 of DNA strands. This illustrates the possibility of cisplatin forming intra-strand crosslinks, and 
transplatin forming inter-strand crosslinks. Taken from ref 200. 
 
There are various forms of DNA adduction with cisplatin, such as 1,2-intrastrand 
crosslinking, interstrand crosslinking, monofunctional adduction, and protein–DNA 






Fig. 1.41. a) 1,2-intrastrand crosslinking; b) interstrand crosslinking; c) monofunctional adduction; d) protein–
DNA crosslinking. Taken from ref 224. 
 
Interstrand crosslinks can also be generated between DNA and cisplatin between two Gs on 
opposite sides of the duplex. It has been shown in the literature that most crosslinks are 
formed as 65% 1,2(GpG) and 25% 1,2(APG). [116] Furthermore, it has been confirmed that 
the intrastrand crosslink between cisplatin and N7 atoms of guanine in the DNA structure (1,2 
strand DNA adduct) can change the DNA structure to bend at 45º. One theory claims that the 
toxicity of cisplatin is caused by this bending form of the double helix, particularly towards 
the major groove. [117]  
DNA repair occurs on the 1,3interastrand crosslink with higher efficiency than at the 1,2 
strand DNA adduct with high mobility group proteins; this is another reason for cisplatin’s 
toxicity in cancerous cells. [18,119] A low concentration of these high mobility group 







Fig. 1.42. Scheme of the cancer cell apoptosis process under exposure to cisplatin. Taken from ref 231.   
 
Various cancer cells, such as ovarian carcinoma, non-small human lung carcinoma and breast 
adenocarcinoma, are resistant to cisplatin.
 
There are a number of reasons for this resistance: 
an ineffective drug dose, cell success in platinum DNA adduct repair, the disabling of 
cisplatin following adduction to the sulphur enzyme, and deactivation of the programmed cell 
suicide pathway. [121]   
Cisplatin’s mechanism of action on mitochondria has not yet been determined clearly; 
however, there is some evidence that the interaction between cisplatin and mitochondria DNA 
could be the reason for cell death. Meanwhile, the interaction of cisplatin with enzymes 
(which contain sulphur) is known to be a reason for cell resistance to cisplatin. [112] 
DNA is regarded as an important target in cancerous cells therapy in many studies. For 
example, the research of Lippard et al. on HeLa cells [121,105] determined that 22 platinum 
atoms are bound per DNA molecule, in contrast to one platinum atom per mRNA, one per 30 
rRNA, one per 1,500 tRNA and one per 1,500 protein molecules. These explain why cancer 
cell lines show wide ranges of response and different patterns of sensitivity to cisplatin.  
Incidentally, the interaction of cisplatin with RNA has received far less attention in the 
literature, although recent research is more focussed on this interaction. There are two reasons 
why it plays a less significant role than the interaction between cisplatin and DNA. First, 




between RNA and cisplatin does not show considerable toxicity against cancer cells in vitro. 
The results represent just 0.1–10% of RNA damage in studied cells. [122] 
 The use of Pt(II) anticancer drugs is limited due to their severe side effects, such as 
nephrotoxicity, neurotoxicity, ototoxicity, nausea and vomiting.
 
[123] To avoid these 
drawbacks of cisplatin, scientists have decided either to use other generations of cisplatin 
analogues, or to create effective non-platinum anticancer compounds such as iron, titanium, 
rhodium and ruthenium complexes. [124] Because of their special properties, these transition 
metals can form complexes with the vast majority of biomolecules as ligands, and can also 
form specific interactions to DNA. These characteristics make them very good alternatives for 
cisplatin. [125,126] 
 
1.4.1.2 Iron-based anticancers 
Iron is an essential element which plays a significant role in biological processes such as 
DNA synthesis. It displays two common oxidation states (+2 and +3), and the transformation 




) via electron transformation is the reason that it 
is a significant element in biological reactions. Moreover, iron unusually exhibits higher 
oxidation states: Fe(V), Fe(VI), Fe(VII) and Fe(VIII), which can play significant roles as 
catalysers in biological oxidation reactions. [127, 128] Accordingly, iron complexes have 
been extensively studied for over a decade as effective anticancers in biological systems.  
With regards to their outstanding biological roles, interest in using iron complexes as an 
anticancer has grown since the early years of the new millennium. Ferrocenium picrat and 
ferrocenium trichloroacetate salts are two of the very first iron complexes used to treat 
cancers (Fig. 1.43). [129] 
 
 





One of the most important characteristics of anticancer drugs is tumour-specific treatment (i.e. 
their tumour-specific action). This ability to act selectively towards molecular targets is the 
cause of reduced side effects in chemotherapy.   
Two thiosemicarbazone-based iron(III) complexes, 5-methyl-3-formylpyrazole-N(4)-
dimethylthiosemicarbazone and 5-methyl-3-formylpyrazole-N(4)-diethylthiosemicarbazone, 
were reported by Ghosh et al. [130] to demonstrate considerable toxicity in HeLa cells. These 
iron complexes with pyrazolyl thiosemicarbazones ligands are able to interrupt and block 




Fig. 1.44. Structures of iron complexes; a) 5-methyl-3-formylpyrazole-N(4)-dimethylthiosemicarbazone, and 
b) 5-methyl-3-formylpyrazole-N(4)-diethylthiosemicarbazone. Taken from ref 129. 
 
The ligand type present in the complex has an important role in the biological properties of 
metallodrugs. Salen ligands and derivatives, such as alkoxyl, hydroxy-, alkyl- or 
trihalomethyl, are known as effective ligands which possess considerable anticancer 
properties. Moreover, iron complexes containing monodentate azole-derived ligands 
demonstrate intense toxicity against various cancer cell lines such as HeLa, A549, A2780, 
MCF-7, G-361 and HOS. The toxicity of these compounds as anticancers in cancer cells are 
far more significant than that of cisplatin in those cells. Figure 1.45a presents one of these 
complexes, which displays severe toxicity against the ovarian carcinoma human cell line 





There are many iron(II/III) complexes with several coordination bonds with chelating ligands 
which play the role of anticancer agents in therapies. Intracellular reactive oxygen species 
(ROS) are generated by iron chelate complexes, and providing a deoxyribonucleotide is the 
cause of DNA damage. Consequently, these complexes deactivate the human ribonucleotide 






Fig. 1.45. a) Iron(II/III) salophen complexes (85–90) containing monodentate azole-derived; b) the structure 
of iron(II/III) salophen complex. Taken from ref 131,136. 
 
In this class, iron(II) bleomycin complex (Fig. 1.46) is one of the most successful anticancers 
that has passed clinical trials to treat testicular carcinoma with high cure rates. [134,135] The 
complex is made by coordinating five nitrogen atoms of bleomycin glycopeptide to an iron(II) 
ion, as the metal centre of the complex. Bleomycin possesses amines, pyrimidine and 
imidazole functional groups in its structure, and is thus an effective N-terminal metal-binding 






Fig. 1.46. Structures of bleomycin A, representing the variety of the molecule’s functional domains. Taken 
from ref 132. 
 
Apoptotic cell death occurs following DNA damage produced by the bleomycin–FeIII_OOH 
complex. This structure is produced by coordinating iron and dioxygen, which subsequently 
provides superoxide (O2
•−
) as a kind of reactive oxygen species (ROS) and a factor of DNA 
destruction. [136]    
The ferrous-triapine
 
complex (Fig. 1.47) is another example of this anticancer class which 




Fig. 1.47. Ferrous-triapine complex structure. Taken from ref 129. 
 
Iron multinuclear complexes with more than one metal centre linked to DNA display different 
modes of DNA binding, such as DNA crosslinking, bisintercalation and DNA–protein 
crosslinking, which make them interesting as anticancer agents.  
The cytotoxicity of iron(III) complexes with the total formula [Fe(salen)(μ-L)]n have been 
studied in different cancer cell lines such as A549, HeLa, HOS, G361, MCF-7, A2780 and 




such as imidazole, 5-methyltetrazole, 5-aminotetrazole, 1,2,4-triazole, benztriazole and 5-
phenyltetrazole. These complexes demonstrate high toxicity against all of the aforementioned 
cancer cell lines. For instance, [Fe(salen)(μ-atz)]n and [Fe(salen)(μ-phtz)]n complexes exhibit 
IC50 values of 0.39 ± 0.05 µM and 0.40 ± 0.17 µM against A2780, respectively. However, on 
average this value is 0.2-0.5 µM against A2780 cells (Fig. 1.48). [138]    
 
 
Fig. 1.48. The structure of [Fe(salen)(μ-phtz)]n complex and its possible optional ligands. Taken from ref 
129. 
 
It is also important to note that some iron complexes have been defined as effective DNA 
strand cleavage agents with promising anticancer activities. For example, tris(diimine)iron(II) 
complexes, rac-[Fe(diimine)3](ClO4)2, have been reported as this class of anticancer. 
Complexes with different diimine ligands display different toxicity against MCF-7 cells; the 
complex with 2,2¢-bipyridine (bpy) as a diimine ligand has an IC50 value of 32 µM, while 
2,5,6-dimethyl-1,10-phenanthroline (5,6-dmp), dipyrido[3,2-d:2¢,3¢-f]quinoxaline (dpq) and 








Fig. 1.49. The chemical structures of tris(diimine)iron(II) complexes with different possible ligands. Taken 
from ref 210. 
 
On the other hand, they display interaction with circulating tumour DNA, and cell apoptosis 
occurs following DNA cleavage after oxidative DNA binding. [140]
  
 
1.4.1.3 Ruthenium-based anticancers 
During the past decade, extensive research has been carried out to find a good alternative to 
platinum complexes for synthesising anticancer drugs. Organoruthenium complexes have 
been found to be some of the most effective non-platinum complexes, and show very good 
results at treating cancerous cells. Ruthenium compounds have displayed various types of 
interaction with DNA, such as covalent binding, intercalation, bisintercalation and groove 
binding. According to the research of Fruehauf and Zeller in 1991 [141], the toxicity of 
ruthenium complexes is dependent on their ability to bind to DNA. Inhibition of DNA 
replication, possession of mutagenic activity, DNA repair and decreased RNA synthesis all 
arise from the way that ruthenium compounds bind with DNA. 
Ruthenium complexes perform the nontoxic transport of iron with high stability in vivo and in 




Ruthenium complexes can also imitate the biological activities of iron, especially in binding 
with significant targets such as DNA. In addition, the low toxicity of these compounds makes 
them a suitable alternative to platinum anticancer drugs, particularly in those cells that are 
resistant to cisplatin. [142]       
The antitumour property of cisplatin is related to its ability to damage DNA arising from the 
square-planar shape of the cisplatin complex. Owing to the octahedral structures of 
ruthenium(II) and (III), the functions of these complexes as antitumours should differ from 
that of cisplatin. 




 and Ru 
IV
) is one of its advantages 
compared to platinum. This redox activation is most important in transferring electrons in 
order for metal-based drugs to play their anticancer role. In addition, ruthenium can form a 
stable complex with an anticipated structure and the ability of substitution rate. The imine 
sides of biomolecules are known as excellent selective targets to bind to ruthenium inside 
cells, in order to generate its anticancer capability. [146] 
There are two ruthenium(III) complexes that have entered clinical trial regulations: NAMI-A 
(imidazolium trans-[tetrachlorido(imidazole)(dimethylsulphoxide) ruthenate(III)) [147] and 
KP1019 (indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)]
 
[149], which affect 
the process of metastasising to prevent secondary cancers by presenting notably low toxicity. 
[148,150]
 
These compounds both perform covalent binding to DNA, despite having different 
mechanisms of action, and both have special characteristics to avoid tumour metathesis in 






Fig. 1.50. Genealogy of ruthenium anticancer drugs from 1980 till the discovery of NAMI-A (the subject of 
clinical evaluation).  Taken from ref 149. 
 
There are some ruthenium(II) complexes (including 2,2'-bipyridine) that, as ligands with low 
toxicity, work as anticancer agents. These structures display fluorescent properties that make 
them suitable for spectroscopic studies. [153] For instance, the ruthenium complex 
[Ru(phen)2(dppz)]
2+
 is used as a fluorescent DNA probe in drug delivery studies. Since this 
complex exhibits fluorescent ability in vivo, after binding to DNA it can become a very good 
choice for study. Moreover, the mode of intercalation of this ligand through DNA can vividly 
alter its fluorescent properties. [154, 155], and the size and charge of ligands has a direct 
influence on intercalating the octahedral metal complex in interaction with DNA. [156]  
Recently, Chen et al. reported the ruthenium(II) complex with the anticancer property of 
causing mitochondrial dysfunction. The complex has a structure of [Ru(MeIm)4(L)]2
+
 (where 
MeIm is 1-methylimidazol and L is 2-(4-chlorophenyl)-1H-imidazo[4,5-f ] 
[1,10]phenanthroline, Ru4, or 2-phenyl-1H-imidazo[4,5-f ] [1,10]phenanthroline, Ru5) and 
was studied in the A549 cell line at the G0/G1 phase. Apoptosis, involving ROS accumulation 
and Bcl-2 and caspase family activation, occurred as a result of interrupting mitochondrial 
activity. [157] The toxicity of this complex is comparable with cisplatin in a vast range of cell 
lines, such as HeLa cells. Its IC50 value against HeLa cells is 27 and 25 µM for Ru4 and Ru5, 






Fig. 1.51. The structure of the ruthenium polypyridil complex, and the X-ray crystal structure of rac-
[Ru(phen)2(dppz)]
2+
 bound to DNA sequence d(ATGCAT)2. Taken from ref 73. 
 
Their DNA affinity can be improved by increasing the number of metal centres, ruthenium 
herein, to enhance the pharmacological activity of drugs accordingly. For example, the 
complex [{Ru(dpq)2}2μ-(phen-5-SOS-5-phen)]
4+ 
exhibits a DNA affinity about 1,000 times 




is in the intercalation class of DNA interactions 







Fig. 1.52. Chemical structures of the ruthenium bisintercalators [{Ru(dpq)2}2μ-(phen-5-SOS-5-phen)]4+. 
Taken from ref 73. 
 
The ruthenium porphyrin complex [Ru(phen)2MPyTPP] exhibits a high affinity for binding to 
the DNA telomere G-quadruplex by noncovalent π–π stacking interaction. [73] Furthermore, 
Zheng et al. reported that the Ru(II) complexes demonstrate a high affinity for binding to c-
myc G4 DNA in groove binding mode, and that cell apoptosis can subsequently occur. [158] 
[Ru(III)(salan)(PPh3)Cl] complex is a new DNA groove binder compound which has shown 
good results in treating ovarian and breast cancers.  
Following intracellular activation by reduction, ruthenium compounds with anticancer activity 
enter tumours and bind to cellular DNA. However, this is only the case where the lone pair 
electron on nitrogen has a tendency to undergo metal ion coordination. Subsequently, most 
often the histidyl imidazole side in protein and the N7 site of imidazole in the ring of the 
purine nucleotide are coordinated selectively by the ruthenium core of the complex. Because 
of differing ligand geometry between their complexes, ruthenium compounds show different 
ability to bind DNA and different cytotoxicity subsequently.  [159]  
Binding between octahedral ruthenium compounds and guanine in DNA chains can provide 




ruthenium complexes play a key role in DNA interaction and form strong bonds with DNA 
strands or with different biomolecules. Accordingly, ruthenium complexes exhibit superior 
abilities to form strong chemical bonds with a vast range of electronegativity and electron 
density. [160] 
Moreover, there is a theory that ruthenium(III) works in a similar way to prodrugs in cells. 
They can be activated after metabolism to an active form of pharmaceutical medicine within 
the body. Therefore, they are less toxic in general than cisplatin. [163,162] It is worth noting 
that the property of reduction (Ru III to Ru II) in vivo plays a significant role for coordinating 
more quickly to DNA, and is termed activation by reduction. The difference between normal 
and tumour cell metabolism is the key to understanding why ruthenium complexes have such 
an important function as anticancers. Due to the fact that the tumour growth process is so fast, 
oxygen and nutrition are used up quickly in these cells. As a result, cancer cells often witness 
dramatic hypoxia as their required energy is made from glycolysis. [163,164] Lactic acid 
resulting from glycolysis metabolism reduces the pH of cells and alters the electrochemical 
potency. The reduction of Ru III to Ru II is made easier under acidic conditions inside 
tumours. There is evidence that Ru II can form a stronger bond to DNA than Ru III, so Ru III 
activation by a reduction in tumour cells (by hypoxia) plays a key role in the toxicity of 
ruthenium(III) complexes in cancer therapy. In contrast, the transformation of Ru II to Ru III 




1.5 Metallo-supermolecular helices 
Helices are special structures found in biological systems, in vital biomolecules such as 
proteins with an alpha-helical shape, DNA with its double-strand helical structure, and triple-
strand helical collagen proteins. Helical structures are formed by organic ligands with 
different coordinating binding sites (capable atoms) that can make a helical axis by 
coordination to metal ions. Visually, it seems that metal ions are wrapped by ligands. 
Helicates are formed by self-assembly; the subunits must be pre-designed, and they therefore 
play a key role in the formation of the helical structure. The planar structure of metal helicates 
depends on the metal coordination number and the number of ligand binding sites. These 
structures are designed with a variety of ligand numbers (one, two and three) and different 




In recent decades, a vast range of metal helicates have been synthesised using different metals 
and ligands such as rhodium, copper, silver, iron and ruthenium. The silver core with a slight 
helical twist was reported by Constable et al. in 1988 [162]; this helicate includes a single 
strand, 2,2’:6’,2”:6”,2”’:6”’,2””-quinquepyridine (La) with five nitrogens as electron donors 
which bind to silver(I) to shape the compact single-strand helicate. [169]  
Many double and triple metal helicates have been recently designed. Metal ions in a double-
strand helix mostly represent four-coordinate geometry, but iron(II), nickel(II) and 
ruthenium(II) are good examples of double-strand helicates that form six-coordinate metal 
centres. Meanwhile, triple-stranded helicates are generally formed by using three-, six- or 
nine-coordinate metal ions.  For instance, the synthesis of triple-strand complexes was 
reported by Zhang and Dolphin in 2010 [170], who reported multinuclear octahedral 




 as nuclear metal ions, and helicates with a 
racemic mixture. [170] 
The helical ruthenium complex designed by Piguet et al. consists of the ligand Lh, as shown 
in Figure 1.53a. This ligand, with its various nitrogen atoms, is capable of donating several 
electrons to ruthenium to make a double- or triple-strand cylinder. A self-assembled 






Fig. 1.53. a) The ligand Lh; b) Piguet’s heteronuclear helicate. Taken from ref 101. 
The supermolecular metal helicates are known as important compounds that possess 
significant anticancer properties in various cancer cell lines. Direct interaction with DNA is 




Special helicates with a DNA major groove binding affinity were designed and synthesised by 
Hannon’s group [194] in order to treat various kinds of targeted diseases, in an effective, 
nongenotoxic and clever way. The pyridylimine ligands (L) (Fig. 1.54) are basic elements of 
helicates with the ability to bind with various kinds of transition metals, such as Fe(II), Co(II), 
Ni(II), Zn(II) and Ru(II), to make a special helicate called a cylinder. [172–174]   
 
 
Fig. 1.54. The chemical structure of pyridylimine ligands (L). Taken from ref 194. 
 
This ligand is synthesised by the reaction between bis(4-aminophenyl)methane and 2-
formylpyridine in ethanol conditions for two hours. The formation of a tetracationic dinuclear 
triple-stranded helicate with the formulation [M2(L)3]
4+
 can be synthesised by a one-pot 
reaction. This cylinder includes three strands of the ligand wrapped around the metal centre. 







Fig. 1.55. Schematic representation of supramolecular cylinder [Fe2L3]4+ synthesis in two steps (L = 
C 25 H 20 N 4).  
 
This complex synthesis produces a racemic mixture of chiral cylinders, M (minus, 
anticlockwise) and P (plus, clockwise) enantiomers. Both enantiomers interact with DNA 
with a minor difference in their DNA binding and coiling abilities. [175]  
 
The iron cylinder is one of the most interesting helical cylinders, and produces very good 
results as an antitumour in many cancer cell lines. The toxicity of this complex has been 
studied for various diseases in vitro during recent decades. [176] The formulation of iron 
supramolecular cylinders comprises two iron ions that wrap with three ligand strands and 
represent a tetra-cationic charge; [Fe2L3] 
4+ 
exhibits a helical structure. The iron cylinder is 
formed easily in a one-pot reaction and, as mentioned above, the racemic mixture of the two 
enantiomers (M and P) results from synthesis. The two right-handed and left-handed 
enantiomers (P: positive, M: negative twisted) are shown in Figure 1.56. [176]  
 
 
Fig. 1.56. The 3D structures of the two iron cylinder enantiomers, M -[Fe 2 L 3 ] 4+ and P -[Fe 2 L 3 ] 4+. 





Surveying the modes of interaction of these enantiomers with DNA demonstrates that both P 
and M enantiomers form strong bonds with DNA, but due to their different chirality, they 
bind to DNA by different modes. H
1
NMR and circular dichroism (CD) spectroscopy show 
that the M enantiomer selects the major groove to bind with normal sequences of alternating 
purines and pyrimidines of DNA, while the P enantiomer may adopt the minor groove, 
spanning the two phosphate backbones. [177] Consequently, the M enantiomer of the cylinder 
forms a more effective noncovalent bond with DNA than the P enantiomer. 
The octahedral spherical shape of the iron and ruthenium complexes and the possibility of 
ligand coordination to form noncovalent bonds with DNA are considered to be important 
characteristics of these cylinders. The free nonbonding pair electrons of nitrogen atoms in the 
ligand structure enable hydrogen bonding to the DNA base pairs. Indeed, the π‐ stacking 
interactions with DNA bases are enabled if the M enantiomer is used for study. There are a 
number of varied studies based on the biological activities of cylinders and their interaction 
modes with DNA. [57,183] 
The iron cylinder shape and size is designed to be similar to the size of a zinc finger protein. 
The correct size of this structure is 2 nm in length and 1 nm in diameter, which makes it a 
good fit into the major groove. [178,179] This similarity to DNA-binding protein motifs make 
it a good option as a DNA replication inhibitor in order to disrupt cell growth, resulting in cell 
death. [180]  
Research outcomes have demonstrated the difference between cisplatin and iron cylinders in 
their mode of action in biological systems. So,Y-shaped junctions are found endogenously in 
cells in the form of DNA replication forks. [181] Research has shown that human telomeric 
G-quadruplex DNA binding is possible with the dinuclear iron(II) cylinder. [182]  
These molecules bind noncovalently and strongly to the major groove of DNA due to 
dramatic binding and intramolecular coiling. The main factor that forms strong noncovalent 
binding to DNA is the contribution between the cationic metal centres of complexes with the 
anionic part of DNA strands. The binding ability of the ruthenium cylinder was studied by the 






The triple helical cylinder can not only bind with the major groove, but can also recognise the 




heart of junctions. The cylinder can also induce unexpected and dramatic intramolecular DNA 
coiling, which gives rise to small coils of DNA; accordingly, DNA is bent by about 45º. 
[184,185]  
Studies on the biological activity of [Fe2L3]Cl4 (L=C25H20N4) reveal that this metal complex 
has an impact on reducing mitochondrial activity in cancer cells. As a result, blocking of the 
cell cycle and cell apoptosis subsequently occur. [187,188] The iron cylinder exhibits toxicity 
in various kinds of cancer cells in vitro, and can potentially be used to inhibit HIV-1 by 
blocking Tat–TAR RNA as a key element of the transaction.  
[Fe2L3] Cl4 has also been reported as an antibiotic that is active against E. coli through binding 
with DNA molecules as a crucial target of therapies. The same study also presented a 3D 





Fig. 1.57. The crystal structure of an iron(II) triple-helicate bound to the junction point of a DNA 3WJ (PDB 
ref. 2ETO). Taken from ref 186. 
 
A variety of cancer cell lines have been treated by three helical iron cylinder complexes, such 
as HBL100, T47D, SKOV3, HL-60 and MRC5, in previous studies. [188] The toxicity of the 
iron cylinder is similar to that of carboplatin against those cancer cells, so it could be used as a 
cisplatin alternative. Moreover, the iron cylinder is a nongenotoxic metallodrug anticancer 
that can exhibit fewer general side effects in therapies. Two incubation times and the amount 
of the drug administered can also play important roles in cytotoxicity on super helical 




The Hannon group have been working on a range of helical systems by designing them with 
different metals and ligands, and are studying their biological effects mainly on DNA in vitro. 
Obviously, these compounds represent different biological activities (such as interaction with 
DNA) in the studied cells, depending on their shape and spherical structure. For instance, both 
ruthenium and iron triple-stranded helices exhibit similar structural characteristics [189,190], 
while the cobalt(III) cylinder ([Co2(L)3]
4+
) displays antimicrobial activity against both 
Staphylococcus aureus and Escherichia coli microorganisms. [191] Moreover, copper helices 
have a slight difference in size and shape to the iron cylinder and are active in the synthesis of 
the nuclease enzyme, which is responsible for breaking the bonds between nucleotides in 
nucleic acids. [192] 
Meanwhile, there is a variety of research on synthesising novel metallohelices by designing 
new ligands and examining their properties through binding with DNA. To this end, hetero 
atoms can be used as a bridge between the two aromatic cycles to change the properties of 
cylinders as well as their resulting affinity for DNA binding and interaction.  
Results show that these ligands can bind to DNA in the same way. A decrease in the thermal 
stability of the ligand unit occurs when oxygen is used as a link between the two phenyl parts. 
[222, 223] In contrast, when sulphur is used instead of oxygen, it causes a significant increase 
in ligand thermal stability. [223] 
The novel chiral derivative of the iron cylinder has been synthesised by adding arginine units 
to the ligand sites, and the cylinder’s anticancer properties were subsequently studied in 
different cancer cell lines. These investigations confirmed that the arginine units promoted 
cylinder cytotoxicity in A2780 ovarian cancer cells. [193]  
This nongenotoxic cylinder can form noncovalent bonds to the Y-shaped DNA junction and 
stall DNA replication, thus driving cells to death. In this regard, arginine plays a significant 
role as an activating part of this anticancer.  
The cellular uptake of supermolecular anticancers is an important challenge in the delivery of 
these drugs. Arginine, as an amino acid involved in direct protein contacts with DNA and 
RNA, plays a key role in improving cellular uptake. Peptides with cell-penetrating ability 
have been applied to improve the cellular and nuclear uptake of ruthenium polypyridyl 
complexes depending on their lysine- and arginine-rich sides and poly-arginine tails. [193]
 
In 




through the effect of grafting arginine residues of the cylinder structure onto the cylinder core. 
[193]  
Although Fe(II) supramolecular cylinders have produced very good results in the treatment of 
various kinds of diseases such as cancers and HIV [194], these compounds have low stability 
in an aqueous solution; this is known to be their disadvantage. Drug stability in aqueous 
solution is considered to be a significant characteristic of drugs applied to biological systems. 
Accordingly, the ruthenium(II) analogue of the iron(II) cylinder is chosen to study for treating 
various cancers in Hannon’s group. [195] The high stability of the ruthenium cylinder 
([Ru2L3]
4+
) in both aqueous solution and biological media is the reason for its selection as an 
alternative to iron in the cylinder structure. [195] 
Fluorescence, CD, LD and X-ray studies are used to characterise the ruthenium(II) cylinder 
[Ru2L3]
4+
 which has the same structure as the iron(II) cylinder, and expresses the same coiling 
and binding modes to DNA. [183] 
There are some differences between the iron and ruthenium cylinders in their activities inside 
cells. For instance, these helical cylinders possess differing cytotoxicity against the same 
cancerous cell lines; the difference in their cytotoxic activity against ovarian and breast (T47D 
and HBL100) cancer cell lines is notable. [197] In addition, under the influence of a UV-vis 
light beam, the ruthenium cylinder has different effects on DNA strands to the iron cylinder, 
causing the DNA strand to break. As a result, DNA cleavage occurs in a sequence-dependent 
fashion at the guanine bases. This is in contrast to the iron cylinder, despite the two cylinders’ 
DNA binding and coiling properties being comparable. [196]  
Using ruthenium(II) instead of iron(II) in the triple-stranded helicate structure can produce 
some difficulties in assembling the cylinder. [195] The synthesis of the ruthenium cylinder 
analogue is a challenge, especially during the purification steps. The resulting low yield of the 
pure cylinder complex (~ 1%) after some purification steps is its drawback. [195] 
The amounts of the ruthenium and iron supramolecular cylinders play a significant role in 
their biological effects. A low concentration of the applied cylinder can cause cell growth and 
multiplication inhibition, and disturbs cell nature growth; conversely, to some extent a higher 
concentration of cylinders can drive cells to self-destruction. [198] These results are not 
independent of the concentration of the cylinder samples used as a drug, rather the amount of 
compound in cells are essential hereupon. [198] Ultimately, the type of cancer cells and the 
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2.1 Synthesis of iron cylinder [Fe2L3]Cl4  
2.1.1 Synthesis of ligand  
In this work, all the required chemical agents were provided by Sigma Aldrich (UK). No 
further purification was carried out. 
In order to prepare the ligand to make the iron cylinder, 3 g (15.2 mmol) of N,N’-bis(pyridin-
2-ylmethylene)-4,4‟-diaminodiphenylmethane was mixed with 2.80 g (30 mmol) of pyridine-
2-carboaldehyde in 50 ml ethanol at room temperature. [1] The mixture was stirred for 12 
hours to completion. The yellow precipitate was filtered by vacuum filtration and was 
recrystallised from ethanol to achieve a purified compound. The resulting product was dried 
under vacuum.  
Yield: (4.9 g, 80%) 
ESI MS: m/z 399 [(C25H20N4) + Na]+.  
1H NMR (CD2Cl2): δ 8.72 (2H, d, J = 3.8 Hz, H6), δ 8.6 (2H, s, Hi), δ 8.23 (2H, d, J = 7.5 
Hz, H3), δ 7.85 (2H, td, J = 7.3 Hz, H4), δ 7.40 (2H, t, J = 7.2 Hz, H5), δ 7.29 (8H, m, HPh), 
δ 4.1 (2H, s, CH2).  
 
2.1.2 Synthesis of cylinder  
0.96 g (4 mmol) iron(II) chloride tetrahydrate was added to 2.72 g (6 mmol) ligand in 160 ml 
methanol and stirred for 2–3 hours under reflux. The purple solution was cooled to room 
temperature and purple iron cylinder precipitate [Fe2L3]Cl4 was separated from solution by 
vacuum filtration. The resulting product was dried under vacuum and purified with methanol 
and diethyl ether. [1]  Yield: (3.83 g, 88%) 
ESI MS: m/z 310 [Fe2(C25H20N4)3]4+. 
1H NMR (MeOD): δ 9.2 (2H, s, Hi), δ 8.71 (2H, d, J = 7.0 Hz, H3), δ 8.49 (2H, t, J = 6.5 Hz, 
H4), δ 7.87 (2H, t, J = 6.1 Hz, H5), δ 7.48 (2H, d, J = 4.2 Hz, H6), δ 6.99 (4H, s, Ha/b), δ 5.6 
(4H, s, Ha/b), δ 4.13 (2H, s, CH2). 
 
The purity of the iron cylinder could have changed over time because of its low stability in 
storage at room temperature or in solution. Taking this into consideration, the synthesis of the 
iron cylinder was repeated every 3–4 months and a fresh solution was used in each test. The 





2.2 Synthesis of ruthenium cylinder [Ru2L3] [PF6]4 
2.2.1 Synthesis of cis-dichlorotetrakis (dimethylsulphoxide) ruthenium 
To synthesise the ruthenium halide complex, 0.2 g of RuCl3 was dissolved in 5 ml of DMSO 
in a 50 ml two-neck flask. The mixture was stirred under an N2 atmosphere for 10 mins. After 
10 mins, the solution heated under reflux for 5 mins. The N2 atmosphere was established 
during the process. 50% of the DMSO was removed after 5 mins by changing the condenser’s 
application. After reducing the solvent by this process, the solution was cooled to room 
temperature, 20 ml acetone was added to the reaction, and a yellow precipitate suddenly 
appeared. It was filtrated by vacuum filtration and washed with cold acetone (10 ml in 2 
portions). The resulting product was dried under vacuum. Yield: 78% 
 
2.2.2 Synthesis of cylinder  
The ruthenium cylinder [Ru2L3](PF6)4 was synthesised under an argon atmosphere to protect 
the reaction from oxidation. The yield of the reaction is not high, so oxidation can block the 
intended reaction or reduce the expected yield, with an increase in unexpected side products. 
To synthesise the ruthenium cylinder, 0.968 g cis-[Ru(dmso)4Cl2] (2 mmol) was added to 30 
ml ethylene glycol and stirred to produce a clear solution, to which 1.12 g ligand L (3 mmol) 
was added slowly. 
The system was set under an argon atmosphere; the neutral gas was purged on top of the 
solution and the oxygen was removed from the vessels by creating a vacuum. The reaction 
was heated under reflux for 5 days to completion. The reaction progress was controlled with 
TLC as it progressed. A brown-orange solution resulted over time. The reaction was cooled to 
room temperature and filtrated from celite. A saturated methanolic solution of NH4PF6 (20 
ml) was made and added to the cold reaction mixture in 5 min. The mixture was stirred on an 
ice bath for 30 mins, followed by storage in a freezer for 24 hours. The brown-orange 
precipitate was vacuum filtrated and washed with cold methanol, diethyl ether and petroleum 
ether. To remove solvent from the product, the wet precipitate was dried under vacuum for 2 
days (resulting in 3.5 g of compound). The TLC was obtained from the impure product with 
the standard sample of ruthenium cylinder to detect the exact place of the cylinder on alumina 




the ruthenium cylinder from the impure compound. A mixture of CH3CN, H2O and KNO3 
(saturated, aqueous) was used as a mobile phase in a ratio of 20:1:1. 50 mg of compound was 
dissolved in 10 ml acetonitrile, and mixed to produce a clear solution. The concentrated 
solution was applied onto an alumina plate and placed into a large tank for 1 hour. The second 
orange band, considered as a ruthenium cylinder band, was scraped from the plate and split 
from the alumina powder by resolving in methanol. The alumina powder and excess 
potassium nitrate was extracted under vacuum filtration in this step. The filtrated product was 
washed with cold ethyl acetate and methanol, and dried under vacuum. [2]  
4.015 mg, yield: 1%  
TOF MS ES
+
 d(CH3CN): m/z (%): 333.08 (100, [Ru2L3]4+), 492.42 (32, 
{[Ru2L3][PF6]}3+), 811.12 (10, {[Ru2L3][PF6]2}2+). 
1H NMR, [Ru2L3](PF6)4 (300 MHz, CD3CN): d = 8.82 (s, 1H, Him), 8.5 (d, J = 3 Hz, 1H, 
H3), 8.29 (t, J = 3,1H,H4), 7.7 (ddd, J = 5.2, 1H, H5), 7.55 (d, J = 5.2 Hz, 1H, H6), 6.98 (d, J 
= 6.5 Hz, 2H, HPh), 5.69 (d, J = 6.2 Hz, 2H, HPh), 4 ppm (s, 1H, CH2 spacer). 
UV/Vis (CH3CN): lmax [nm] (e [m_1cm_1]): 485(24,200), 445 (17,600), 320 (45,500), 270 
(71,300) 
 
2.3 Cell culture 
The U2OS cell line culturing method is described below. All cell culture must be undertaken 
in microbiological safety cabinet using aseptic technique to ensure sterility. 
 
2.3.1 Cell line 
Currently, knowledge about protein expression in the human osteosarcoma U2OS cell line 
and the effect of cylinders is very limited, despite its extensive applications in the field of 
biomedical research. [3]
 
U2OS (ATCC number HTB-96): osteosarcoma; bone sarcoma from the tibia of a human 
female. 
2.3.2 Complete media preparation 
Gibco
®
 by life technologies
TM
 16600-082 McCoy's 5A Medium (modified) [+] L-glutamine is 




supports the growth of primary mammalian cells derived from normal bone marrow, skin, 
spleen, kidney, lung, rat embryos and other tissues. 
McCoy's 5A (modified) Medium was supplemented with foetal bovine serum (10% v/v), 
penicillin (100 U/ml), streptomycin (100 μg/ml) and L-glutamine (2 mM). The complete 
media was stored in the fridge at 4 °C. [5] 
 
2.3.3 Cell cultures 
The U2OS (osteosarcoma) cell line was removed from storage at -80°C and pre-warmed to 
thaw in a 37 °C water bath. In addition, PBS and complete McCoy's 5A Medium were also 
warmed at 37 °C.  
Thawed cells were resuspended in 10 ml of PBS in 10 ml falcon tubes, and were then 
centrifuged at 1,500 rpm at 25°C for 5 mins to remove the growth medium containing DMSO. 
The pellet was resuspended in 200 µl fresh medium and then transferred to 25 ml of complete 
media in a 75 cm
3
 tissue culture flask with a vented cap (T75) (Costar). Cells were incubated 
at 37 °C in a 5% CO2, 95% air incubator to grow (Sanyo, MCO-17A). The media was 
changed every 2 days and cells were passaged every 2 or 3 days and split cultured when they 
reached 85% confluence. [4] 
 
2.3.4 Subculturing of U2OS cells 
Once cells were confluent, they were passaged. Complete media, trypsin-EDTA (Gibco®) 
and 0.01 M phosphate buffered saline (PBS) (Sigma-Aldrich) were warmed in a 37 °C water 
bath. The aspirated growth media was taken carefully from the culture flask and washed with 
10 ml of PBS to ensure that the entire surface was cleaned from the old media. PBS was 
removed from the cultured flask and 2–3 ml of trypsin (depending on cell confluence) was 
added to the flask. The flask was incubated at 37 °C for 2–5 min, before it was tapped to 
dislodge the cells and checked under the microscope to ensure the cells detached more than 
70–90% confluent. fresh media was added (8 ml if 2 ml trypsin was used, and 7 ml if 3 ml 
trypsin was used, in order to produce a maximum 10 ml mixture). 
To inhibit the trypsin and the contents of the flask, they were transferred to a 15 ml falcon 
tube. The cell suspension was centrifuged for 5 mins at 1,500 rpm at room temperature, and 
the supernatant was discarded. Suspended cells in 200 µl of fresh media and cells were mixed 




added to each part in a new T75 flask. Both flasks were incubated in an incubator at 37 ºC and 
5% CO2. [4,5] 
 
2.3.5 Storage of U2OS cells 
Extra cells (2–5×10
6
 cells/ml) after two or three episodes of re-culturing were frozen to 
maintain an appropriate stock of viable cells. Cells were checked for bacterial, yeast or fungal 
contamination under a microscope. The old media was removed and trypsinised by a standard 
protocol, as described in section 2.3.4. Cells were resuspended in new media and were then 
centrifuged at 1,500 rpm at 4 °C for 5 min. 
Supernatant was removed and the pellet was immediately resuspended with 1 ml of frozen 
media containing 5% DMSO in vials. The vials were placed on ice and labelled with name, 
date and cell type. They were stored overnight in a freezer at -80 °C, then transferred to a 
liquid nitrogen tank. [5] 
 
2.3.6 Maintenance of cell cultures (in T75 flasks) 
Cell cultures were maintained in T75 flasks containing 15 ml of fresh media. These flasks 
were placed in a humidified incubator at 37 °C and 5% CO2. The flasks were examined daily 
under the microscope for signs of contamination and general cell morphology. 
Every 2 days, the old media was removed from the T75 flask. 10 ml of PBS was added to the 
flask and then removed to eliminate any dead cells. 15 ml of complete media was then added 
to the flask, and the flask was placed back into the incubator. [5] 
 
2.3.7 Cell counting  
To count cells, the hemocytometer and cover slip were cleaned, thoroughly dried and 
assembled. As described in section 2.3.4, cells were washed with PBS and trypsinised for 2 
mins, then centrifuged to split the pellet. The pellet was resuspended in 1×10
3
 µl media. Cell 
dilution (1:10) was performed by the addition 10 μl of the suspension to 90 μl of fresh media 
in an Eppendorf. 20 μl of dilution suspension was then pipetted under the edge of each of the 
two counting chambers, and allowed the cell suspension to be drawn into the counting 
chamber by capillary action. The hemocytometer was then placed under a microscope and 




device and the number of any viable cells in each square was recorded. The average number 
of cells was calculated and multiplied by the dilution factor. 
If the cells have not been diluted, this factor is 10
4
 cells/ml. Any dilution of the sample after 
removal from the cell suspension (such as when using vital stain) needs to be included in the 
calculation. The number of cells was calculated according to the following equation: 




2.3.8 Cell viability 
To count viable cells, 0.4% trypan blue solution in PBS was made, and the solution was 
incubated for 2–5 mins before loading. The cell suspension was mixed 1:1 with 0.4% trypan 
blue solution. Dark blue cells were detected as unviable cells and cell viability was calculated 
as the number of unstained cells divided by the total number of cells, and expressed as a 
percentage. [5] 
 
2.4 MTT-based cytotoxicity assay 
2.4.1 Survey of the cytotoxicity effect of synthesised metallodrugs on U2OS cells 
Subconfluent monolayer U2OS cells maintained in a T75 flask were trypsinised to collect the 
cells in growth medium. The suspension was centrifuged (5 min at 1,500 rpm) to pellet 
the cells and removed the supernatant. To count the viable cells, cells were resuspended in 
1,000 µl of medium. A Neubauer haemocytometer was used to count the cells. Cells were 
diluted to 2.5–10×10
4 
cells/ml. The cell suspension was then transferred to a 9 cm petri dish 
and 200 µl of the suspension was added to each well of a flat-bottomed 96-well plate. Seeding 
the cells began from column number 2 and ended with column number 11, 8 wells columns 
number 1 and 12 were used as control lines in each plate. The plate was left in the incubator at 
37 °C and 5% CO2 for 24 hours, to ensure that there were enough adherent cells on the wells’ 
surface. [5] 
2.4.2 Preparation of drugs 
To survey the toxicity of iron and ruthenium cylinders in U2OS cell lines, 2,500 µM stock 




To make fresh stock solution of the iron cylinder, 9.101 mg of cylinder powder was solved in 
2 ml of deionised autoclaved water and was mixed to homogenise completely. 1.5 mg of 
cisplatin was solved in 2 ml of deionised millipore autoclave water and mixed carefully to 
create a homogenised solution, which was used fresh. 
A stock of ruthenium cylinder was prepared using Beer-Lambert’s law and a UV 
spectrometer. 2 mg of the cylinder was solved in 500 µl of acetonitrile, and the λmax was 
used to establish the concentration of ruthenium cylinder in acetonitrile by applying the Beer-
Lambert equation for concentration. Acetonitrile was vacuumed from the solution and mixed 
with DMSO-water (1:1) to have a 2,500 µM stock solution. 
 
2.4.3 Evaluating the cytotoxic effects of ruthenium and iron cylinder treatment 
Following incubation for adherent cells, the medium was removed very carefully from each 
well in columns 2 to 11, and 200 µl of fresh medium (warmed up to 37 °C) was added to each 
well from columns 2 to 11. Cells were then treated with various concentrations of iron 
cylinder and cisplatin in water (0, 5, 10, 15, 20, 25, 75 and 150 µM) in plate 1, and with 
ruthenium cylinder and cisplatin (0, 5, 10, 15, 20, 25, 75 and 150 µM) in DMSO (or in the 
mixture of DMSO and water to have less than 1% DMSO in each wells) in plate 2. Water and 
DMSO were applied as a positive control in plates 1 and 2, respectively. Two plates were 
wrapped in plastic sheets and left in an incubator in 5% CO2 at 37 °C for 72 hours (2–3 
PDTs).  
Following incubation, wells were washed with 37 °C warmed PBS three times to remove the 
drugs completely, and 200 μl complete growth medium was then added to columns 1–12.  
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) solution was 
prepared in PBS (5 mg/ml). 50 μL of MTT was added to every well in columns 1–11. 
The plates were incubated for 2 hours in a humidified atmosphere at 37 
◦
C. Following 
incubation, the media was removed from each well and the remaining purple MTT-formazan 
crystals were dissolved by adding 200 μL of DMSO to every well in columns 1–12. DMSO 
(200 μl) was also added to the empty column 12 to serve as a blank. The absorbance was 
recorded immediately (because the product is unstable) with a plate reader at an absorbance 
setting of 570 nm (BIO-TEK, FL600, with KC4 software). The converting of MTT into 
formazan occurs after cell death, so the colour transformation from yellow (MTT) to purple 
(formazan) is the best marker to define the viable cells. Reading was done from column 1–12; 




percentages of viable cells were calculated using the average absorbance of the two readings 
(DMSO was blank adjusted, with the control set to 100%).  
 
2.5 Imaging microscopy 
Confocal microscopy was used to examine the effects of cylinders on U2OS cells, and to 
establish where they have an influence on DNA. [6] 
 
2.5.1 Live cell microscopy 
2.5.1.1 Qualitative analysis 
Live cell imaging allows real time monitoring of cell treatment. Cultured U2OS cells were 
trypsinised and 2×10
5 
cells were counted and placed in each dish for live-cell imaging. Petri 
dishes with covered glass bottoms were used for live-cell imaging (35 mm glass-bottom dish, 
dish size 35 mm, well size 20 mm, cover glass (0.085–0.115 mm). 200 µl of fresh media was 
added to each dish and incubated overnight until cells were adherent. Cells were labelled 
with Hoechst 33258 before carrying out microscopy. 500 µl of 5 mg/L Hoechst solution was 
added to each dish and they were incubated for 20 mins at 37 °C. Dishes were removed from 
the incubator and wrapped in aluminium foil immediately. They were then taken to a dark 
room under a hood; Hoechst was removed completely from MatTeks and cells were washed 
twice with 1 ml of warmed PBS. 200 µl of media was added to each dish, and they were 
wrapped again. A Nikon Eclipse Ti epifluorescence microscope (40x oil-objective) was used 
for fluorescent imaging of U2OS cells. Cells were treated with various concentrations of 
ruthenium and iron cylinders (0, 15, 25, 50 and 100 µM) under a hood. Images were taken 
every 30 mins (before and after the treatment) from each concentration of cylinder and 
DMSO (6 samples treated with cylinders, 2 negative control samples and 3 positive control 
samples with DMSO) for 2 hours. The laser was turned off following image capture to 
prevent photo-bleaching. The samples were maintained at 37 °C by means of a heated stage 






2.5.1.2 Quantitative analysis 
8×10
4 
cells were counted and cultured in 200 µl fresh media in each wells of multi- well 
MatTeks (8-well cell culture slides, 12 × 5 × 2.5 inch). MatTeks were incubated overnight till 
cells attached to surface. 40 µl of 5 mg/L Hoechst solution was added to each dish and 
incubated them for 20 mins at 37°C. Dishes were removed from incubator and wrapped in 
aluminium foil immediately. Dishes were taken to dark room under hood, Hoechst was 
removed completely from MatTeks and cells were washed with 300 µl warmed PBS twice 
with multiple gun. 200 µl of media was added in each dish and they were wrapped again. 
Nikon Eclipse Ti epifluorescence microscope (40x oil-objective) was used to do fluorescent 
imaging from U2OS cells. Cells were treated with various concentrations of ruthenium and 
iron cylinders: two wells were assigned to negative controls; two wells were allocated to 
positive control with 2 µl DMSO; two wells were allocated to positive controls with 
autoclaved deionised water; and 4 other wells were assigned to ruthenium cylinder and iron 
cylinder. Cells were treated with 50 µM concentration of each cylinder in 200 µl of media 
(ruthenium cylinder was used from 5000 µM stock solution in DMSO and iron cylinder was 
used from 5000 µM stock solution in water). Images were captured before the treatment and 
every hour after the treatment for 3 hours. The laser was turned off following image capture to 
prevent photo-bleaching. The samples were maintained at 37 °C by means of a heated stage 
under a CO2 atmosphere. Images were analysed after captured with ImageJ/FIJI programs. 
 
 2.5.2 Fixed-cell microscopy 
Cell staining is a technique that can be used to better visualise cells and cell components 
under a microscope. To perform fixed-cell microscopy, 10×10
6
 U2OS cells per well were 
cultured on glass microscope slides, which were placed into multi-well microscopy dishes 
(three 8-well microscopy dishes), and 1 ml fresh medium was added to each well. Dishes 
were incubated overnight. The next day, adherent cells were washed with warm PBS once, 
and 200 ml fresh medium and 40 µl of 5 mg/L Hoechst solution was added to each well. 
Dishes were incubated from 20 mins, Hoechst was removed completely, and cells were 
washed twice with warm PBS. 300 µl fresh media was then added to each well again. Dishes 
were protected from light to prevent photo-bleaching during the process. 1.5, 3, 6 and 12 µL 
of ruthenium cylinder stock (2,500 µM) in 50:50 DMSO-water was used to treat cells. 1.5, 3, 
6 and 12 µL iron cylinder stock (2,500 µM) in water was added to wells to treat cells. In every 




control. For ruthenium treatments, 1.5, 3, 6 and 12 µL of 50:50 DMSO-water was added to 
wells as a control, and 1.5, 3, 6 and 12 µL of water was used as an iron cylinder control. After 
2 hours of incubating dishes in the incubator, cylinders were completely removed from each 
well and washed with 300 µl PBS three times. 
300 µl formalin was added to each well, and they were incubated at room temperature for 10 
mins. Formalin was removed and the wells were washed three times with PBS. Cell plates 
were removed from wells with extra PBS on the correct side and were washed once again 
with PBS and once with water. A small oil drop was placed on the microscopy slide and the 
cell plate was placed from the cell site onto the oil. It was then pressed gently to remove 
bubbles. Slides were stored in a box and placed in the fridge to set. 
 
2.6 Protocol for uptake studies of the ruthenium cylinder in adherent tumour cells 
2.6.1 Cell preparation 
Cells were trypsinised for 2 min at 37 °C in an incubator. The suspension of cells and media 
was then centrifuged at 1,500 rpm for 5 min at room temperature. The pellet was resuspended 
in 1 ml medium and viable cells were counted, with the 0.4% trypan blue solution in PBS 
applied (as described in section 2.3.8). In order to have a negative control sample alongside 
the sample treated with the cylinder, two 10 mm petri dishes were prepared by seeding with 
5×10
6
 cells in 10 ml complete growth media. The dishes were left in an incubator for 24 hours 
at 37 
°
C under 5% CO2 to ensure that they adhere completely to the dishes’ surface. 
 
2.6.2 Compound treatment preparation 
An appropriate concentration of drug to treat U2OS cells in this process was found after 
treating the cells in an MTT assay test with ruthenium cylinder. To obtain the best results of 
cells’ drug uptake levels, the highest toxic concentration of cylinder was considered as an 
equal concentration in an ICP-MS test to treat cells; in this way, 50 µM was considered to be 
an optimum concentration of ruthenium cylinder. Considering the fact that using DMSO in 
biological systems has a limitation range due to DMSO toxicity, 2% of DMSO was found to 




To make 2,500 µM stock solution of ruthenium cylinder in DMSO, the UV-vis 
spectrophotometry technique and Beer-Lambert law were employed when measuring the 
absorbance of the solution. 
 
𝐴 = 𝜀. 𝑙. 𝑐                                 [1] 
 
The Beer-Lambert equation (equation [1]) was used to find the concentration. In equation [1], 
𝐴 is absorbance (since  𝐴 =  𝑙𝑜𝑔 
𝑃0 
𝑝
), 𝜀 is the molar absorptivity with units of L mol-1 cm-1, 𝑙 
is the path length of the sample in cm (that is, the path length of the cuvette in which the 
sample is contained) and 𝑐 is the concentration of the compound in solution, expressed in mol 
L
-1
. The epsilon for ruthenium cylinder in acetonitrile is 16,895 L/mol.cm. Subsequently, 
about 2 mg of ruthenium cylinder was solved in 500 µl of acetonitrile and the absorbance of 
the solvent was read at λmax: 16,895 cm
-1
. The concentration was checked and corrected using 
the Beer-Lambert equation. The acetonitrile in the optimum sample was evaporated 
completely and an equal amount of DMSO was added to the sample (of pure ruthenium 
cylinder) and vortexed, to produce a 2,500 µM stock sample of ruthenium cylinder.  
 
2.6.3 Compound treatment 
Following 24 hours of incubation, 200 µl of the stock solution was added to 10 ml media in 
one of the prepared petri dishes that was labelled as a test, or T. The second petri dish was 
considered as a positive control; 200 µl of DMSO was added and the petri dish was labelled 
as a control, or C (the same solvent was used at the same time to make it blank). Petri dishes 
T and C were both incubated for 4 hours until cells had uptaken the drugs.  
 
2.6.7 ICP-MS   
After 24 hours, cells were washed several times with warmed PBS to remove complex excess. 
Cells were trypsinised, then centrifuged at 1,500 rpm for 5 mins at room temperature to make 
a pellet. The pellet was resuspended in 600 µl of growth medium, then 20 µl of the suspension 
was counted with the hemocytometer. The cell suspension was divided into two equal 
amounts of S1 and S2. S1 was kept as a test sample and used for fractionation using a kit. 
Meanwhile, S2 was kept as a sample of the whole cell and labelled with this name. The same 




To separate the nucleus from the cytoplasm, the Nuclear/Cytosol Fractionation Kit 
(BioVision, Catalog#K266-25) was used.  






Table 2.1. The table of kit contents. 
 K266-25 K266-100   
Component 25 assays 100 assays Cap code Part number 
Cytosol extraction buffer A (CEB-A) 5 ml 20 ml WM K266xx(x)-1 
Cytosol extraction buffer B (CEB-B) 300 µl 1.2 ml Green K266xx(x)-2 
Nuclear extraction buffer A (NEB) 25 ml 10 ml NM K266xx(x)-3 
DTT (1M) 100 µl 100 µl Blue K266xx(x)-4 
Protease inhibitor cocktail 1 vial 1 vial Red K266xx(x)-5 
  
 
2.6.7.1 Reagent preparation  
Initially, an ice box was prepared to ensure that all buffers, inhibitors and extractions were 
kept on ice during the experiment. Then, 250 µl of DMSO was added to 500X protease 
inhibitor cocktail to solve it before use, and it was placed on ice. 
For the experiment, a sufficient amount of cytosol extraction buffer A (CEB-A) and nuclear 
extraction buffer A (NEB) were prepared before starting the procedure. 2 µl of protease 
inhibitor cocktail and 1 µl of DTT were added to each 1 ml of CEB-A and each 1 ml of NEB, 
individually, and they were kept on ice ready for use. 
 
2.6.7.2 The fractionation protocol 
After 4 hours of incubation, cells from both petri dishes were trypsinised and then centrifuged 
at 1,500 rpm for 5 min. The pellets were resuspended with 1 ml growth medium and each was 
divided into two different vials. The cell numbers were counted with a hemocytometer and 
recorded. Two samples (S2 and C2) were kept on ice at 4
°
C as whole cells (sample whole 
cells and control whole cells).  
The kit protocol was followed for both S1 and C1 at the same time. Cells were collected by 
centrifugation at 600×g for 5 mins at 4 
°




DTT and protease inhibitors was added to the cell pellets. The mixtures were vortexed 
strenuously for 15 seconds at the highest speed. The cell pellets were incubated on ice for 10 
mins before 11 µl of 0–4 
°
C cytosol extraction buffer-B was added to the tubes. Tubes were 
vortexed at the highest speed for 5 seconds and then incubated on ice for 1 min. The vials 
were vortexed on the highest setting for 5 seconds. Tubes were centrifuged with a 
microcentrifuge at the high speed of 16,000×g for 5 mins at 4 
°
C. 
The supernatant (cytoplasmic extract) fractions were immediately transferred to a clean pre-
chilled tube and placed on ice. The pellets (containing nuclei) were resuspended in 100 μl of 
ice-cold NEB mix. The samples were vortexed on the highest setting for 15 seconds and the 
samples were then returned to ice. This step was repeated 8 times every 10 mins, for a total of 
40 mins. Tubes were centrifuged at 16,000×g for 10 mins at 4 
°
C. The supernatants (nuclear 
extract) were immediately transferred to the clean pre-chilled tubes and were placed on ice. 




2.6.7.3 Sample preparation 
To prepare the samples, all cell fractions were transferred to clean vials. To clean the vials, 
they were washed very carefully (they were initially washed for 30 min in HNO3 5%, the 
HNO3 was washed in Distilled Deionized (dd) water for 30 min, vials were cleaned for 15–30 
min in methanol and 15–30 min in acetone, then dried completely in a clean oven. Contact 
with any solvent or dirt was avoided). 
After cleaning the vials, the cellular fraction was transferred into vials and 2 ml of HNO3 
70% (Traceselect Ultra Aldrich) was added to each one. Vials were kept in a freezer at -80 
°
C 
overnight for digestion. Samples were transferred to falcon tubes the next morning. Ultrapure 
water was added to each vial to dilute the HNO3 to 5%, and falcon tubes were kept on ice for 
analysis. 
 2.7 Alkaline comet assay  
Comet assay is a technique used to measure DNA damage from treating cells with a drug, 
which combines DNA gel electrophoresis with fluorescence microscopy. It aims to visualise 





2.7.1 Cell preparation 
2×10
6
 cells were cultured in 3 separate 6-well plates and were incubated overnight in an 
incubator at 37 
◦
C. Each plate had 3 columns and each column had 2 rows (A and B). The 
cells in plate 1 were treated with 3 different concentrations of ruthenium cylinder (15, 25 and 
50 and 100 µM); plate 2 was treated with 3 different concentrations of iron cylinder (15, 25 
and 50 and 100 µM); and plate 3 was treated with cisplatin in column 1 as a positive control. 
Column 2 was used as the negative control. 
 
2.7.2 Preparation of buffers and slides 
2.7.2.1 Lysis buffer 
To make the lysis buffer, 146.4 g of NaCl, 37.2 g of Na2EDTA.2H20 and 1.21 g of Tris base 
were dissolved in 800 ml H2O to give 2.5 M NaCl, 0.1 M Na2EDTA.2H20 and 10 mM Tris 
base. The pH was set at 10 with NaOH pellets and pH was checked continuously with a pH 
meter, which was calibrated with standard solutions before the test. 33.3 ml sodium lauryl 
sarcosinate was added to the solution, which was then made up to 1 L with deionised water. 
The lysis buffer was stored at 4 
°
C in a cold room.  
 
2.7.2.2 Neutralisation buffer  
24.6g Tris base was solved in 500 ml deionised water; the pH was adjusted using HCl to 7–
7.5 and the solution was stored at 4 °C in cold room. 
 
2.7.2.3 Electrophoresis buffer 
Initially, two stock solutions were made. The 9 M stock solution of sodium hydroxide was 
prepared with a mixture of 180 g NaOH pellets in 500 ml deionised water (stock A), and the 
200 mM stock solution of Na2EDTA.2H2O by solving 37.2 g of its powder in 500 ml 
deionised water (stock B). 80 ml of stock A and 12 ml of stock B were then mixed together to 
produce 300 mM NaOH and 1 mM EDTA. The solution was made up with deionised water to 
2,400 ml and was stored at 4 
◦





2.7.2.4 Preparation of slides 
0.5% w/v normal melting point agarose (NMPA) solution was prepared by dissolving 1 g 
NMPA powder in 200 ml dd H2O, which was then warmed in a microwave to dissolve the 
agarose completely. The evaporated H2O was compensated and cooled down to around 60 
°
C 
before use. Slides were prepared 1–2 days before the experiment. To make the slides, ¾ of 
clean frosted slides (unfrosted portion) were dipped in molten NMPA one by one, and the 
agarose was cleaned from the underside of the slides. Slides were then left horizontally to dry.  
 
2.7.2.5 LMPA preparation 
To prepare the 5% (w/v) LMPA solution, 1 g LMPA was dissolved in 200 ml PBS in a 
microwave for 5 mins and stored at 37 °C. 
 
 2.7.2.6 SYBR gold staining solution preparation 
1 µl of concentrated SYBR gold staining was dissolved in 1 ml deionised water and used 
immediately. This amount was enough for 20 slides. 
 
2.7.3 Comet assay procedure 
After 4 hours of treating cells, drugs and medium were removed from wells and washed 3 
times with 2 ml pre-warmed PBS. 300 µl of PBS was added to each well and scraped 
carefully to detach cells from the surface without using trypsin. The mix of cells and PBS was 
transferred into an Eppendorf and then labelled with the correct name. Cells were centrifuged 
with a micro-centrifuge at 13,000 rpm for 5 mins. The pellet split from PBS and responded it 
in 150 µl of PBS. An ice-cold silver tray surface was prepared 5 mins before starting the 
procedure. 15 µl of the cell suspension was mixed with 150 µl of warmed molten LMPA in a 
new Eppendorf, which was then vortexed for 15 seconds to mix completely. 150 µl of 
suspension was transferred onto coated slides, which were labelled with their information and 
a cover slip was placed gently on top. Slides were placed on an ice-cold surface for 20 mins to 
solidify. After solidification, cover slips were removed from the slides and a mixture of lysis 
buffer containing 10 ml DMSO, 89 ml lysis buffer and 1 ml Triton X was transferred into a 
coplin jar. Slides were placed into jars, wrapped with foil and placed in a cold room for 1 
hour. Slides were then removed from coplin jars and placed into an electrophoresis tank from 




mins. The instrument power pack was turned on at 32 V, 300 mA and electrophoresed for 20 
mins.   
Slides were removed and washed with neutralisation buffer 3 times for 5 mins, before they 
were washed with dd water once and then again for 5 mins. 50 µl SYBR gold solution was 
added to each slide and covered with a cover slip. A moist box was made, where slides were 
placed and carefully covered with foil. The images were taken by microscope via 40x oil 
objective one by one. 
 
2.8 Western blot technique 
The highly important method of western blotting, which uses gel electrophoresis to separate 
native proteins by 3D structure or denatured proteins by polypeptide length, is a tool for 
protein identification and relative quantitation in complex samples. This technique combines 
size-based electrophoretic separation with immunoaffinity to identify specific proteins. 
2.8.1 Cell preparation and treatment  
Cultured cells were trypsinised and centrifuged to produce a pellet, which was resuspended in 
1 ml PBS and counted by a hemocytometer. 1.5×10
6
 cells were seeded in 18 different 10 cm 
dishes and incubated overnight to inherent cells. The next day, cells were treated with 
different concentrations of iron cylinder (50, 200 and 500 µM), ruthenium cylinder (50, 200 
and 500 µM) and cisplatin (5 and 50 µM) for 1 hour and 24 hours. Cisplatin was considered 
as the positive control and two untreated dishes were considered as negative controls after 1 
and 24 hours. In total, two treatment times were used for each compound and concentration. 
All of the dishes were washed with 2 ml pre-warmed PBS, then trypsinised for 2 mins. Cells 
were centrifuged at 3,000 rpm for 5 mins to make a pellet. Split pellets were washed once 
with cold PBS. Cells were pelleted again and all PBS was removed with 200 µl tip carefully. 




2.8.2 Cell lysis 
For lysis cells, a UTB buffer was made with a mix of 8 M urea, 50 mM Tris base and 150 mM 
mercaptoethanol. To make 100 ml of UTB buffer, 75 ml dd water was heated in a water bath 




cooled to room temperature, and 0.61 g Tris base and 1.172 ml beta-mercabthanol were added 
to the urea solution. The pH was then adjusted to 7.5. 
Next, 100 µl UTB lysis buffer was added into each frizzed cell Eppendorf. Cells were 
sonicated on ice (2 cycles, max power for 10 mins). Samples were then centrifuged at 13,000 
rpm at 4 °C for 20 mins with a benchtop centrifuge.     
2.8.3 Bradford protein assay 
In the Bradford protein assay, colour changes (from orange-brown to blue) resulting from the 
binding of protein molecules to Coomassie dye under acidic conditions is investigated 
(colourimetric assay). This technique helps to measure the concentration of total protein in a 
sample. 
1 mg/ml bovine serum albumin (BSA) in PBS was prepared as stock solution. 0, 1, 2, 3, 4, 5 
and 10 µg/µl standards were prepared from stock. Each sample was diluted with dd water to 
1/10 by adding 36 µl of dd water to 4 µl samples. 10 µl of the standard samples were added to 
18 wells of a 96-well plate (6 columns each of A, B and C rows). 5µl of each sample was 
transferred into wells. 200 µl of Bradford buffer was added to the wells, and the plate was 
incubated in a dark room for 5 mins. The plate was read on a plate reader, and the 
concentrations were calculated for the preparation of lysates to load 20 µg protein/gel. 
 
2.8.4 Gel electrophoresis 
2.8.4.1 Gel, buffer and solution preparation 
A. 10% SDS  
10 g sodium dodecyl sulphate (SDS) crystals were dissolved in 90 ml water. SDS crystals 
were solved at 68 °C. The pH was checked with a pH meter and then adjusted to pH 7.2 with 
the addition of HCl. The volume was made up to 100 ml with water and the solution was 
stored at room temperature. 
 
B. Tris solution (0.5 M, pH 6.8) 
60.57 g Tris(hydroxymethyl)aminomethane was solved in 800 ml water. The solution was 
autoclaved for 24 hours and pH was adjusted to 6.8 with 100 ml HCl 37%. The volume was 
made up to 1 L with water and the solution was stored at room temperature. 
 




181.71 g Tris(hydroxymethyl)amoniumethane was dissolved in 800 ml water and was 
autoclaved for 24 hours. The pH was adjusted to 8.8 with the addition of 40 ml HCl 37%, and 
the volume was made up to 1 L with water. The solution was kept at room temperature. 
 
D. Make10X Laemmli buffer stock 
30.25 g Tris base and 144.20 g glycine were solved in 650 ml water. 100 ml 10% SDS was 
added to the solution. It was then brined up to 1 L with dd H2O, and diluted to 1X for running 
gel. 
 
E. Make 6X SDS loading buffer 
7 ml 0.5 M Tris and 1 g SDS were dissolved by vortexing for about 5 mins. 3 ml glycerol, 1.2 
mg bromophenol blue and 680 μl mercaptoethanol were mixed with the solution. 
 
F. Make staking gel 
To make staking gels, 11 ml water, 2.4 ml acrylamide 30%, 5 ml Tris solution (0.5 M, pH 6.8) 
and 200 µl SDS 10% were mixed together and kept at room temperature. 
 
G. Make running gel 
To make two running gels, 15.8 ml water, 13.4 ml acrylamide 30%, 10 ml Tris solution (1.5 
M, pH 8.8) and 400 µl SDS solution 10% were mixed and stored at room temperature. 
 
2.8.4.2  Protocol 
For gel electrophoresis, the gel apparatus and glass plates were cleaned thoroughly with soap 
and water and rinsed with ethanol. They were left to air dry and were then assembled. Two 
gels were made for each cylinder: one for the CK1 protein and one for P-CK1. Gels were 
made of two different gel phases: running gel at the bottom of plates, and staking gel at the 
top. Two gels were made up as described in steps F and G in the section above. The running 
gel was mixed with 400 µl APS 10% and 40 µl TEMED to set, and plates were immediately 
poured with 7 ml of complete running gel. 1 ml/gel butanol (H20-saturated) was added to the 
top of each gel to reduce bubbles, and was left to set for 20 min. Gels were checked after 20 
mins (the remaining gel in the tube was examined to establish whether the gels had set well) 
and they were washed appropriately with dd water to completely remove butanol. Staking gel 




on top of the running gels in the plate. Combs were then inserted at an angle (to prevent the 
formation of bubbles). The spaces on both sides of the combs were checked to ensure that all 
wells had complete walls before they were left to set. During the setting time, samples were 
prepared through mixing with a loading buffer (20 µg/gel, 5X; see the data from the Bradford 
protein quantification in Table 3.2.) and boiling in a heating block for 10 mins at 100 °C, then 
centrifuged with 1,300 rpm for 20 mins at 4°C. Once the stacking gel was set, the combs were 
gently pulled out of the gel and the wells were washed out with dd H2O. The tank was filled 
inside and outside with 1X Laemmli buffer. The samples and marker were loaded in their 
wells and electrophoresis was performed with 75 V and 0.09 A for 90–120 mins. 
 
2.8.5. Protein transfer 
In this step, the protein was transferred from gel to membrane, which is conventionally made 
of a chemically neutral substance such as nitrocellulose or polyvinylidene difluoride (PVDF). 
 
2.8.5.1  Preparation of buffer and solutions 
The following buffer and solutions were used in this step of the process. 
 
A. Transfer buffer 
5.8 g glycine and 11.6 g Tris was dissolved in 400 ml methanol, and the solution was made up 
to 2 L with water. 
 
B. Block 
25 g milk powder was dissolved in 500 ml TBS-T and stirred to solve completely, then stored 
at 4 °C in a fridge. 
 
C. TBS 10X 
60.5 g Tris and 87.6 g NaCl were mixed with 800 ml dd water to have a pH of 7.5, then 
adjusted to 1 L with the addition of dd water. 
 
D. TBS-T 1X 





2.8.5.2 Protocol  
To transfer the gel to a membrane, a nitrocellulose membrane (one sheet per gel) and 
Whatman paper (two sheets per gel) were cut and prepared before the procedure. Gels were 
removed from the tank, and to remove them from between the glass plates, a green wedge was 
used to gently pry the glasses apart. This was carried out in a tray of transfer buffer. Gels were 
removed easily from slides into the liquid, but were picked up very gently because of their 
fragility. They were assembled in cassettes in a particular way, to transfer proteins to the 
membrane in the correct orientation. Assembly proceeded by this rule; the entire setup was 
located in a Tupperware container full of transfer buffer. The layers were set from the black 
side to clear side as follows: black side, pad, paper, gel, membrane, paper, pad, clear side. 
Layers were rolled with a glass rod to roll out bubbles. Cassettes were then closed tightly and 
placed in a tank in the correct orientation. The tank was filled with transfer buffer, which was 
cooled with an ice pack from the 20 °C freezer and stirred with a stir bar. Electrophoresis was 
performed at 100 V for 1 hour. Membranes were removed carefully and floated in Ponceau 
solution for 5 mins. They were then washed with TBS to remove the red colour. The excess 
length of membranes was cut, labelled and placed in block solution for one hour at room 
temperature with agitation. Membranes were placed in a primary antibody overnight. Two 
membranes were for ruthenium cylinder and two others for iron cylinder. One membrane of 
each group was placed into 2 ml of a mixture of 1 µl CK1 (CK1 (G-4)-10t: A17-13, Santa 
Cruz Biotechnology) antibody in 10 ml block solution. The other two membranes were placed 
into 2 ml of a mixture of 10 µl CK1-P (Phospho-ChK1 (Ser345) antibody, # 2341L) in 10 ml 
BSA or TBS-T. They were kept overnight in a cold room with agitation. 
 
2.8.6 Development 
Membranes were removed from the bag. The antibodies were recovered and washed in 50 ml 
TBS-T for 10 mins three times. Secondary antibodies were diluted in block (16 µl of anti-
mouse was diluted in 50 ml block, and 50 µl of anti-rabbit was diluted in 50 ml block). 
Membranes were placed in their antibody for 1 hour at room temperature with agitation, and 
were then washed three times in 50 ml TBS-T. A chemiluminescent solution was used to 
develop them (5 ml of HRP swostrate peroxide solution (WBK L0500milipore) was mixed 
with 5 ml of HRP swostrate luminal reagent (WBK SØ500milipore)), which membranes were 




between the plastic sheets in the cassette. The film was placed (cut into ¼ pieces) at the 
bottom right corner of the other side of the cassette in a dark room, and the cassette was 
closed tightly for 1 min. Film was then run through the developer. The ladder was traced in 
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 3.1 Introduction 
Today, different types of cancer are treated by methods such as surgery, radiotherapy and 
chemotherapy. Among these treatment strategies, chemotherapy is considered to be an 
effective way to fight cancers because it uses chemistry to manipulate the biochemistry and 
way of survival of cells. Various anticancer drugs and medicines have been designed in recent 
years to treat a variety of cancer types by preventing their ability to grow and divide. 
In contrast to surgery and radiotherapy, which specifically target cancerous organs and 
tissues, chemotherapy can have various effects on all organs of the body. Depending on the 
types of medicines used in a chemotherapy treatment, an extensive range of side effects can 
be produced. To avoid the destruction of normal cells by chemotherapy, in recent decades 
many research activities have focussed on designing targeted (or ‘smart’) drug delivery as a 
new pathway for developing less aggressive chemotherapy drugs. Cell cycle drugs are 
desirable because they have fewer side effects as anticancer drugs, and they can enhance a 
patient’s quality of life during the treatment. 
Cancer cells are classified into two groups: proliferating cells and non-proliferating cells. 
Depending on the class, different approaches must be applied in their treatment. [1]
 
Small molecules, hormones and other kinds of antineoplastic drugs are used to inhibit or kill 
the cell growth progress in proliferating cancer cells. For instance, DNA replication is 
impeded by anticancer drugs; accordingly, topoisomerase enzymes can be inhibited as an 
impact of this process. Cell biochemistry can be altered by disordering protein synthesis as a 
result of topoisomerase enzyme inhibition, which can stop cell growth or drive cells to death. 
[2,3] 
While targeting DNA is now known to be an effective approach to address the cancer 
problem, it is also important to consider the possible disadvantages and complications that 
may arise from choosing this treatment strategy. The significant side effects of this line of 
treatment can include an increase in the chance of developing secondary cancers resulting 
from damaged DNA, which should be taken as a huge drawback. Some small molecules such 
as cisplatin – a well-known and effective drug classified under the alkylating group of 
anticancers – can form permanent covalent bonds with DNA. Such a permanent change might 





In this study, ruthenium and iron cylinders are used to treat osteosarcoma (U2OS) cells, which 
are classified as high proliferation cancer cells, with DNA-targeted anticancer drugs. 
It is expected that both cylinders stop the replication fork and transcription process, by 
blocking the DNA groove through the formation of noncovalent bonds with DNA, and 
disorder the cell growth progress, by changing the biochemical processes inside cells, thereby 
killing cancer cells due to their high toxicity and lack of genotoxicity effect.  
 
3.2 Fluorescenc microscopy 
To study the effects of ruthenium and iron cylinders on U2OS cells, Fluorescence microscopy 
was used to establish how they uptake and localise in cells (i.e. the uptake process). In 
contrast to the iron cylinder, the ruthenium cylinder has a fluorescent property that provides 
the possibility to directly study its activity in cells by Fluorescence microscopy, although it 
does not have an intensive absorption. So, in both cases, a better strategy for imaging is 
required. Therefore, to demonstrate noncovalent bonding in the cylinders and to determine the 
location of their attraction to DNA, an auxiliary fluorescent probe was used in this research. 
Fluorescence microscopy is frequently used in life sciences to investigate biomolecules and 
their interactions and connections to each other through labelling of biomolecules and 
organelles. This technique enables the use of multiple lasers combined with a fluorescent 









Fluorescence is the emission of light accompanying relaxation of a molecule from an excited 
state to its ground state. In this technique, electrons are excited to unoccupied LUMO state 
orbitals (with higher energy levels) due to the adsorption of photons; when they relax and 
return to ground state, the vibrational energy is lost, and thus the emission spectrum is shifted 
towards longer wavelengths. 
Molecules with this property are called fluorophores. These structures frequently contain 
many aromatic rings, long conjugate bond networks and, frequently, hetero atoms. Three 




Rhodamine Anthracene Fluorescein 
Fig. 3.2. The structures of some fluorescent compounds.  
 
Fluorescent probes are essential factors in nucleic acid imaging, for both live- and fixed-cell 
imaging. Fluorescent labels are designed depending on the location of their interaction with 
DNA and RNA. Fluorescent gene probes are classified into three groups: sequence-specific 
DNA bonding peptides and proteins, triplex-forming oligonucleotides gene targeting and 
groove binders. In most studies, these repeated DNA sequences, which are localised in the 
specific loci of chromosomes, such as centromeres or telomeres, have been used as targets. 
The local concentration of the desired sequence is quite high and it can therefore be detected 
with the fluorescent probes. [9,10] 
Polyamides with conjugate minor groove binders are understood to be better choices because 
of the fact that fluorophore probes must have high cellular uptake and penetration, stability in 
various physical conditions (live-cell microscopy) and the ability of easy detection. 
Fluorophore stain stability is considered to be an important property of DNA probes; 
fluorescent probes mostly lose their fluorescent ability during the imaging process (during 
photo-bleaching or dye photolysis). The photo-bleaching phenomenon is a photochemical 




Hoechst is a blue stain minor groove DNA binder with high specificity and low background, 
which is used in both live- and fixed-cell microscopy. It is a bis-benzimide derivative that can 
be classified into three groups: Hoechst 33258, Hoechst 33342 and Hoechst 34580.  
 
Hoechst 33258 R=OH 
Hoechst 33342 R=OEt 
Hoechst 34580 R=N(Me)2 
Fig. 3.3. The Hoechst structure. Taken from ref 12. 
 
Hoechst is a minor groove binder stain with a tendency to bind to the AT reach sites of 
double-strand DNA. Its fluorescent intensity is increased when it forms a bond with DNA. 
Kinetic studies have demonstrated high rates of association constants Ka of Hoechst 33258 to 
DNA AT reach sites. The affinity of Hoechst binding to DNA produces AATT as the 
strongest binding sequence and TATA, like TTAA, as the weakest binding sequence. [13] 
To survey the cell uptakes of cylinders and to determine the position of their action on DNA, 
Fluorescence microscopy imaging was used as an effective technique. The additive factor was 
used to help with detection of the nonfluorescent iron cylinder as a minor groove DNA 
binder. 
In this method, Hoechst was used as a DNA fluorescent probe to bond with the DNA minor 
groove; the displacement of Hoechst with iron cylinders was the basis of the investigations 
presented here. Hoechst 33258 is excited at 350 nm and emits at 461 nm, while Hoechst 
33342 is excited at 352 nm but also emits at 461 nm. While Hoechst 34580 used in these 
experiments is excited at 370 nm and emits at 437nm. In addition, ruthenium cylinder 
interaction with DNA was studied using this technique. The ruthenium cylinder has 





3.2.1 Live cell imaging 
Iron and ruthenium cylinders are able to interact with the major groove and replication fork 
junction of DNA. In this way, they can inhibit DNA replication and destroy cell growing 
paths. Examining cylinders’ modes of action and their sites of localisation are the goals of this 
investigation. Since Hoechst (the blue fluorescent probe) demonstrates interaction with the 
minor groove of DNA, it can be considered as a suitable indicator to find the location of 
cylinder action. Previously published research has demonstrated that the Hoechst blue colour 
was bleached when iron or ruthenium cylinders replace Hoechst on the minor groove of DNA.  
To carry out live-cell microscopy, U2OS cells were cultured in MatTeks and incubated with 
Hoechst 34580 for 20 mins before imaging. Blue dye was washed completely with PBS, and 
medium was added to each dish again. Cells were imaged with a Nikon microscope with 
different channels to record all changes in the vast range of absorbance. Images were taken 
before treatment from the test and negative and positive control MatTeks. In the initial test, 
the first sample was treated with the minimum effective concentration, 25 µM, of iron 
cylinder, while the second sample was treated with 15 µM of ruthenium cylinder. A negative 
control was used to assess the process in samples with compression. Consequently, the 
negative controls act as evidence to differentiate photo-bleaching from Hoechst displacement. 
In addition, 1% of DMSO was used as a positive control to expose U2OS cells to ruthenium 
cylinder solvent and investigate its impact on the cells (i.e. Hoechst replacement or 
bleaching). 
To capture images of the samples, they were observed through a DAPI blue fluorescence filter 
with 75 nm bandpass within the 420–495 nm range. The blue colour of Hoechst was observed 
in the nucleolus of cells in all samples before treatment. To confirm the fact that the 
ruthenium cylinder has absorbance at 488 nm, cells were also checked by an FITC green filter 
in spectral regions of 450–500 nm. The cells did not show a green shade before treatment. 
They were also checked with a DAPI-FITC dual band fluorescence filter combination, where 
all samples showed a blue colour only in images. 
Images were captured after 1 and 2 hours of treatment and did not show a marked contrast in 
the intensity of the blue colour compared with the primary images and negative control 
sample. The blue shade of Hoechst remained remarkably blue, whereas the green colour was 
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Fig. 3.4. Live imaging in different channels of U2OS cells treated with 15 µM ruthenium cylinder: a) positive 
control imaging after 2 hours (the image original size was 2048 x 2048 pixels, with 0.16 micron / pixel scale 
means 328 µm x 328 µm); b) imaging of samples before treatment; c) imaging after 1 hour of treatment; d) 






In Figure 3.4d, cells appear to be alive with healthy membranes, but some changes can be 
observed around the nucleus area. After 2 hours, the blue and green shades decrease and the 
membrane still looks healthy, but the damage around the nucleus area is increased. In the 
positive sample test there is no significant difference between images before and after 
treatment, meaning that cells appear to be alive and no damage is observed in the membranes 
or around the nucleus area. Notably, Hoechst displacement was not observed in any of the 
samples in this test. 
Following the previous test, U2OS cells were treated with 0, 15, 25, 50 and 100 µM of 
ruthenium and iron cylinders to check the effect of a high cylinder concentration on Hoechst 
replacement (Fig. 3.5). Even though concentrated cylinder samples were used in this test, the 
final results were similar to those of the first experiment. 
Figure 3.5 shows the U2OS cells treated by 50 µM ruthenium cylinder for 2 hours. Initially, it 
appears that the ruthenium cylinder was replaced with Hoechst due to the reduction in the 
intensity of the blue colour over 2 hours. In addition to this observation, the green colour that 
was absorbed in the FITC filtration channel flourishes and then declines in its intensity during 
imaging, but the blue colour fades simultaneously. The green colour is a sign of the existing 
ruthenium cylinder in cells which was not initially observed in the green channel, but was 
made to fade by Hoechst during the imaging time. Despite the observations of the first test, 
Hoechst could have been replaced by a highly concentrated solution of ruthenium cylinder 
over 2 hours. 
However, the option of light bleaching following multi-capture imaging is possible; therefore, 
quantitative imaging was carried out to assess the results. Alternatively, the green colour of 
the ruthenium cylinder might appear as a result of hydrogen bonds formed with Hoechst and 
the formation of long conjunction bonds to improve fluorescent adsorption. Subsequently, it 
faded due to Hoechst at the same time. In other studies, the green shade in the FITC filtration 
channel has been explained differently, and presented as a Hoechst photoproduct with 
emission at 458 nm.
8
 Fixed-cell microscopy was carried out to eliminate the photo-bleaching 
element from the process, and to enable cells to be studied by removing environmental 
effects. The ruthenium cylinder adsorption at 458 nm (the green channel) was checked by 
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Fig. 3.5. Live imaging in different channels of U2OS cells treated with 50 µM ruthenium cylinder: a) samples 
before treatment; b) after 1 hour of treatment; and c) after 2 hours of treatment. ( the micron bar shows the 
scale of 10µm) 
































3.2.2 Fixed cell imaging 
Fixed-cell microscopy is a type of Fluorescence microscopy whereby cells are fixed and 
killed with formaldehyde before imaging. This is known as chemical fixation, which applies 
special compounds to preserve cell structure, both chemically and structurally, to be as close 
as possible to a living tissue. Fixation protects cells by the destruction of biochemical 
processes within them, such as autolysis and putrefaction. This is typically done by disabling 
intrinsic biomolecules (particularly enzymes) which may otherwise digest or damage the 
sample. Fixation causes cell death, and the mechanical strength or stability of supermolecules 
and cells are increased by chemical fixation at the molecular level. [16] 
In the first test, U2OS cells were cultured in multi-well dishes and on microscopy circle 
slides. After one night, the adherent cells were treated by 0, 12, 25 and 50 µM iron and 
ruthenium cylinders for 2 hours and washed with PBS several times, in order to totally 
remove the cylinders. Cells were fixed with 10% formalin and then fixed on microscopy 
slides with oil. Cells were stained by Hoechst (33258) 20 mins before the treatment, in order 
to observe Hoechst replacement by cylinders. An untreated sample was fixed as a negative 
control, to observe the fluctuations in Hoechst adsorption intensity for comparison with 
treated samples. Fixed slides were imaged by a Nikon microscope using the same program as 
live microscopy, and with the same settings for all slides. 
The images represent the same result as in live microscopy, because Hoechst replacement was 
not observed completely in treated samples when compared to the controls. Figure 3.6 shows 
that Hoechst is observed in the cell nucleus after 2 hours of treatment with ruthenium 
cylinder, and the blue colour in the picture was captured by DAPI filtration (Fig. 3.6d) shows 
that the stain was not replaced by ruthenium cylinder. The green colour in Figure 3.6b does 
not show the same location as the blue colour in Figure 3.6d; this can be explained by the 
green colour as a sign of ruthenium cylinder existence in cell parts, particularly the nucleus. 
However, since ruthenium cylinder with its special structure is itself fluorescent and highly 
photo sensitive, the treated cells were imaged without staining by Hoechst. This was done in 
order to recognise the ruthenium cylinder cell uptake and the location of its effects by 









Fig. 3.6. Fixed cell imaging of U2OS cells treated with 25 µM ruthenium cylinder after 4 hours: a) dual filter 
DAPI-FITC (420-500 nm); b) FITC filter (450-500 nm); c) ND; and d) DAPI filter (420-495 nm). ( the 








Fig. 3.7. Fixed-cell imaging of U2OS cells treated with 50 µM ruthenium cylinder using FITC filter (458 nm). ( 
the micron bar shows the scale of 50µm)  
 
After several trials of fixed-cell microscopy, the ruthenium cylinder was observed inside the 
cells (Fig. 3.7).  
 
3.3 MTT assay cytotoxicity 
MTT assay is a practical technique to discover the toxicity of cylinders in U2OS cells. This 
method is part of the class of colourimetry techniques that use MTT to measure cell viability. 
In this method, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is used 
to detect the population of live cells. [17] 
A free electron was generated in the process of transferring the NADH to NADP in the 
metabolic activity of mitochondrial live cells. The reduction of the tetrazole part of the MTT 
structure opens the tetrazole ring and makes formazan; consequently, the yellow colour 





Fig. 3.8. Scheme of the mitochondrial reduction of MTT (yellow solids) to purple formazan in live cells. Taken 
from ref 19. 
 
DMSO is used to dissolve the insoluble formazan to make a coloured solution, which is 
necessary for reading with a UV spectrophotometer. The concentration of purple formazan 
represents the live cell population that can be checked at 510 nm by a UV spectrophotometer 
plate reader. [20] 
During the test, U2OS cells were cultured in 98 multi-well plates and treated with ruthenium 
cylinder, iron cylinder, cisplatin, DMSO and water to determine their cytotoxicity for 
osteosarcoma cells. To obtain accurate results, different drug concentrations were used to treat 
cells. 
As an important anticancer drug for various types of cancers, cisplatin was considered as a 
standard sample for test evaluation. Its use as a positive control makes it possible to compare 
these results of cisplatin cytotoxicity in U2OS cells with those of other published works. 
Moreover, to evaluate the results of ruthenium cylinder cytotoxicity in U2OS cells compared 
to cisplatin, DMSO was used as a solvent of cisplatin as well as water, to provide two 
different positive controls (i.e. cisplatin in DMSO and cisplatin in water) in this test. 
3.3.1 Results and discussion 
To determine the minimum concentration of ruthenium and iron cylinders toxicity in U2OS 
cells, the cells were treated with various concentrations (0, 5, 7.5, 10, 15, 20, 25, 75 and 150 
µM) of cylinders for 72 hours. Initially, DMSO as a ruthenium cylinder solvent was used as a 
positive control in U2OS cells in different percentages (0, 1, 2, 3, 4, 5 and 6). This test 
demonstrated that a concentration of higher than 1% DMSO is toxic for the cells, and that 
50% of cells were killed when 2.5% DMSO was used as a control in treating. Accordingly, 




subsequently producing a total concentration of less than 1% DMSO in the samples. As an 
example, 0.6 µl from the 2,500 µM stock of ruthenium cylinder in DMSO was added to 300 
µl media in wells (A1, A2, A3 and A4) to obtain a 5 µM concentration overall. As a result, 
0.2% DMSO was used in these treatments. In contrast, in high concentration treatment (75 
and 150 µM), a 5,600 µM stock of ruthenium in DMSO was used for the treatment. For 75 
µM treatment, 8 µl of stock was diluted in 8 µl of dd water and 4 µl of the mixed solution was 
added to 300 µl of medium in the intended wells, to give a total of 0.6% DMSO. There are 
published works that demonstrate the application of cisplatin to treat U2OS cells. 
Consequently, cisplatin was used as a positive control in this study. Cells were treated with 
various concentrations of 0, 5, 10, 15, 25, 75 and 150 µM ruthenium and iron cylinders four 
times under the same conditions. As well as cisplatin in water and in DMSO, water and 
DMSO as a positive control was used with the same concentration to treat cells. Plates were 
read at 570 nm by a plate reader after 72 hours from the start of treatment. The results suggest 
that ruthenium cylinder with an IC50 value of 18 µM is more toxic in U2OS cells than iron 
cylinder, with IC50 26 µM. The samples treated with cisplatin in water lost just 20% of their 
cell viability in total, while using cisplatin in DMSO for treatment resulted in a 40% loss of 























Fig. 3.9. Results of the MTT assay for evaluation of cell viability: a) cells were exposed to the indicated 
concentration of ruthenium cylinder, iron cylinder, cisplatin in water and cisplatin in DMSO; b) U2OS cells 




Nevertheless, this data may indicate that the U2OS cell line is resistant to cisplatin. This 















toxicity of cisplatin (3.9 µM) in U2OS cells. Similarly, 5.6–8.6 µM has also been given as the 
cisplatin toxicity in this cell line. [21,22] Despite these reports, there are other published 
works showing that U2OS cells are resistant to cisplatin. [23,24] In contrast to the results of 
cisplatin solved in DMSO and water, Hall and his co-workers [48] found the negative impact 
of DMSO on cisplatin and other platinum complexes as an inactivator element. This means 
that the structure of cisplatin can be changed by replacement of cisplatin ligands with DMSO.  
According to the microscopy and MTT assay results presented in sections 3.2 and 3.3, while 
iron and ruthenium cylinders exhibit their toxicity in U2OS cells, Hoechst replacement was 
not observed even after 24 hours. Consequently, to find the location where cylinders affect the 
DNA, their cellular uptake was tested by ICP-MS. 
 
3.4 Cellular uptake 
Inductively coupled plasma mass spectrometry (ICP-MS) is a sensitive, accurate and 
multifunctional type of mass spectrometry which makes it possible to precisely detect low 
concentrations of elements, such as metal and nonmetal ions at or below a single part per 
trillion (ppt) level in samples. A vast range of elements can be determined by ICP-MS with 
the instrumental detection limit shown in Figure 3.10. [25] 
 
 





This technique is widely used in a range of fields such as toxicology, medicine and forensics. 
[27] As an example, it is used to trace the amounts of metal elements in drugs uptaken by 
cells for various purposes. Nevertheless, ICP-MS can be used to quantify the amount of iron 
and ruthenium uptaken by cells after treatment. 
To investigate the amount of iron and ruthenium uptaken by U2OS cells, and to detect their 
separate amounts in cell parts, cells were treated with a single 50 µM concentration of 
ruthenium cylinder and iron cylinder in two separate flasks for 4 hours. DMSO was used as a 
positive control. Different parts of cells were separated, so that supernatant and nucleus 
fractions resulted from the fractionation process. Supernatant is a cytoplasmic extract that 
includes the cytoplasm organelles. To normalise all parameters, all samples were produced 
under the same conditions. The dark orange colour of ruthenium cylinder was observed in all 
cell fractions, indicating that cell uptake was confirmed visually. The purple colour of iron 
cylinder was observed in every cell fraction with the exception of the membrane, which 
remained as a solid part from the end of the fractionation process. 
 
 
Fig. 3.11. a) Fractionation samples of U2OS cells from both treatments (iron cylinder and ruthenium 
cylinder), parts 1 and 2; b) scheme of the last part of cells following the fractionation process, including the 
cell membrane; this shows that the main portion of ruthenium cylinder was trapped in the cell membrane (the 
dark orange colour remained in the Eppendorf). This is in contrast to iron cylinder; in this figure, the last 








The average cellular amount (Cc) of the respective metal (fg cell
−1
), as well as the related 
standard deviation (scc), can be calculated using Equation 3.1:  
 
            [3.1] 
 
 
where Cc is the average cellular amount (fg cell
−1
), Ct the average measured metal 
concentration in the uptake samples (‘total concentration’, ng ml
−1
), cb is the average 
measured metal concentration of the adsorption samples (‘blank concentration’, ng ml
−1
) and 
N is the average cell number (cells well 
−1
). [32] 
The results showed that 26% of ruthenium cylinder was uptaken into U2OS cells, 74% of 
which was trapped inside the cell membrane (as shown in Figure 3.12). From this calculation, 
16% of ruthenium was detected in the nucleus and 10% was detected in the cytoplasm. 
 
 





This process was simultaneously performed for iron cylinder, but Fe is hard to assess 
accurately by ICP-MS because of the levels of Fe found in the environment, glassware and 
solvents including nitric acid.   
 
3.5 DNA damage detection  
Despite the fact that antineoplastic drugs are designed to treat growing cancer cells, they can 
also be the cause of triggering secondary cancers in patients due to their gene mutation ability 
or their genotoxicity. Some anticancer drugs, such as cisplatin, have shown genotoxicity to be 
their disadvantage. Accordingly, research on the effects of anticancers on genes, particularly 
on DNA, is highly desirable. To measure DNA strand breakage in eukaryotes, single cell gel 
electrophoresis assay (SCE), or comet assay, can be used as an accurate method. In this 
technique, treated cells are suspended in agarose gel, lysed with detergent to remove cells and 
nuclear membrane, and electrophoresed to draw out the charged fragments of DNA towards 
the anode. This is then stained with fluorescent DNA dye to enable image capture by 
Fluorescence microscopy. [28,29] The comet-like images display a spherical head and DNA 
breaking within their tail (Fig. 3.13). The amount of DNA damage is proportional to the 
comet’s tail length, meaning that greater DNA breakage results in more DNA in the comet’s 
tail. [31] 
 
Fig. 3.13. Different parts of the cell ‘comet’: the head (undamaged DNA) and tail (damaged DNA). Taken 
from ref 30. 
 
There are two different comet assay methods, depending on the lysis pH: neutral comet assay 




published studies [29] that only double-strand breaks are detected with neutral pH, even 
though both single- and double-strand breaks can be detected by applying an alkaline pH. It is 
worth noting that single-strand breaks are not considered to be a significant lethal or 
mutagenic lesion on DNA due to their fast repair ability. A pH of above 13 can break the 
alkali-labile AP (apurinic/apyrimidinic) sites of DNA made by genotoxic agents. Alkali comet 
assay is therefore a popular technique for DNA damage detection. [29] 
In the literature, iron and ruthenium cylinders have exhibited nongenotoxic effects in various 
types of cancer cell lines. To investigate their effects on the genome of U2OS cells, the cells 
were treated with 15, 25, 50 and 100 µM of ruthenium and iron cylinders in multi-chamber 
plates for 4 and 24 hours, with two wells being allocated for each concentration to increase 
accuracy. To calibrate the test, untreated cells were used as a negative control to exemplify 
minimum DNA damage, and hydrogen peroxide (H2O2) was used as a positive control to 
treat cells and cause maximum DNA damage. Although U2OS cells show cisplatin resistance 
in the results of this study, cells were treated by 50 µM of cisplatin (meaning minimum DNA 
damage) for comparison with ruthenium and iron cylinders. In addition, 1% DMSO was used 
to treat cells to evaluate its impact on DNA and to compare the results with the negative 
controls. 
Importantly, many different parameters can affect the comet tail, such as the lysis conditions, 
electrophoresis time and agarose gel loading quality. Thus, negative controls play a 
significant role in producing reliable results for comparison. Moreover, to assess the results 
statistically, it is essential to sum the value of 100 randomly selected comets to provide a total 
damage level of the cell population, and it is also necessary to repeat the entire process at least 
three times for the sake of accuracy. 
Depending on the level of DNA damage, comets can be found in different shapes: a higher 
chromatin mass together with a lower comet tail concentration are indications of a lower level 
of damage, while more damaged DNA results in lowering the chromatin mass, followed by an 





Fig. 3.14. Classification of comets on the basis of DNA damage level. Taken from ref 31. 
 
 
3.5.1 Results and discussion  
The results show that iron and ruthenium cylinders are not genotoxic in U2OS cells, 
suggesting that the imaged comets did not represent a high concentration of DNA breakage in 
their tail lengths (see Fig. 3.15 and Table 3.1). Moreover, to compare the iron and ruthenium 
cylinder comets following treatment with 50 µM (a high concentration of cylinders for 
treatment) after 4 hours (the minimum time of treatment) and 24 hours (the maximum time of 
treatment), as shown in Figure 3.15, the comets can be classified on a scale of damage from 0 
to 1.  
  
(a) (b) 
Fig. 3.15. Demonstration of cell comets after 24 hours of treatment by 50 µM of cylinders; a) iron cylinder, 





The results of U2OS cell treatment with cisplatin produced the observation of DNA damage 
in comet tails after 4 and 24 hours of treatment. These comets can mostly be classified in the 
damage level class of 2, and less so in the damage class of 3. Considering the MTT assay 
results, which showed that U2OS cells are slightly resistant to cisplatin, it is unsurprising the 
dramatic DNA damage was not observed in U2OS cells after this treatment. 
 
 
Fig. 3.16. The state of cell comets after treatment with 50 µM cisplatin for 24 hours. 
 
According to Figure 3.15, 1% DMSO is not toxic in U2OS cells in the captured images. The 
comets had a class 0 DNA damage level, as observed in Figure 3.17. 
 
 
Fig. 3.17. The state of U2OS cell comets treated with 1% DMSO after 24 hours. 
 
The maximum damage results from the 1% H2O2 used as a positive control. A dramatic 
reduction in chromatin mass and the tail length of comets compared to the positive controls 





                                       (a)                                                                      (b) 
Fig. 3.18. U2OS comets; a) the negative control after 24 hours; b) the positive control of 1% H2O2. 
 
The comet assay results of U2OS cells treated with ruthenium cylinder (15, 25, 50 and 100 
µM), iron cylinder (15, 25, 50 and 100 µM) and 50 µM of cisplatin solution in water after 24 
hours are presented in Table 3.1. 
 
Table 3.1. The average DNA tail migration in U2OS cells treated by various  
concentrations of ruthenium cylinder, iron cylinder and cisplatin as a negative control. 
 














Iron cylinder Cisplatin 
0 0.1±0.08 0.1±0.08 0.1±0.08 
15 1.12±0.04 1.02±0.03  
25 1.6±0.38 1.34±0.15  
50 3.08±0. 3 2.93±0.25 16.03292 
100 8.2±0.2 6.6±0.32  





Fig. 3.19. The median DNA tail migration of U2OS cells exposed to different drugs and conditions. 
 
 
According to Figure 3.19, cylinders did not demonstrate total genotoxicity in U2OS cells. 
However, when 100 µM of ruthenium cylinder was used to treat cells, it showed a maximum 
strand breaks (8.2%) which was almost similar to the DNA tail migration of the iron cylinder 
(6.6%). This dose (100 µM) is far higher in concentration than the effective dose of ruthenium 
cylinder (15 µM) and iron cylinder (25 µM). Accordingly, DNA could be damaged in a high-
stress situation, particularly by a high dose of ruthenium cylinder in DMSO and cisplatin does 
not exhibit dramatic DNA damage in U2OS cells (16%). 
 
3.6 Protein immunoblotting 
Protein immunoblot, which is a crucial technique in cellular and molecular biology, is 
referred to by different names in the literature, including protein blotting or western 
blotting. Essentially, this technique is applied to identify the existence of an individual 
protein within a complex mixture extracted from cells. Western blotting is used to separate 
proteins from cell lysate by applying gel electrophoresis to sort them by their size, charge or 




protein electrophoresis which, depending on their function, can provide specific information 
about proteins. As an example, nondenaturing poly-acrylamide gel electrophoresis (PAGE) 
separates proteins based on their mass-to-charge ratio; two-dimensional (2D) PAGE separates 
proteins by native isoelectric point in the first dimension, and by mass in the second 
dimension. [33] 
Blotting is the process of transferring the segregated protein bands to the safe career called 
membrane, which could be made of nitrocellulose, nylon or PVDF. [33,35] 
There are some significant aspects which are worth mentioning, as the western blot results 
make this technique routine for visualising protein bands; the size-based separation of protein 
mixtures using gel electrophoresis is a practical way to transfer the separated proteins to a 
solid support. In addition, it offers the possibility of a rapid and inexpensive method for 
detecting a target protein by appropriately matched antibodies. [34,35] Protein 
immunoblotting is an effective method for recognising and targeting specific proteins from 
various complex sources, to investigate the contribution or effects of disease in normal cells 
and to understand how the targeted protein responds to treatment drugs. 
 
3.6.1 Bradford protein assay 
The process is initiated by Bradford protein assay as a spectroscopic analytical technique to 
measure the total concentration of protein in each prepared lysate sample. [33,35] 
Coomassie Brilliant Blue G-250 dye is used in this colourimetric protein assay to measure the 
converting absorbance of dye before and after application. The fundamental part of this 
procedure is that the colour of the Coomassie Brilliant Blue G-250 dye changes from orange-
brown to blue when bonds are formed between the dye and proteins. Unbound dye has a 
maximum absorbance of 465 nm, and the negative charge produced by binding to proteins 
increases the maximum absorbance to 595 nm. [36,37] Crucially, binding occurs between 
some simple amino acids such as histidine, arginine and tyrosine with dye in acidic 
conditions. The intensity of the blue colour represents the protein concentration in each 
sample. [36,37] 
To perform Bradford assay, cells were lysed using a UTB buffer. Cell disintegration was then 
sonicated on ice to break and to disrupt cell membranes and to homogenise the lysate, to 




samples is difficult to measure, using a standard curve produced from standard proteins was 
used as a common method to eliminate computational errors and to provide accurate protein 
determination. Reference proteins should be chosen based on their properties, which should 
be similar to the proteins of analysed samples, such as BSA or bovine γ-globulin (IgG). BSA 
was used as a standard protein at various concentrations of 0, 1, 2, 3, 4, 5 and 10 µg/µl. At 
least six standard samples should be prepared to create a standard curve. Protein calculation 
was performed to prepare 20 µg of protein per gel for the following samples: a) samples 
treating cells with 50, 200 and 500 µM iron cylinder for two different treatment times of 1 and 
24 hours; b) samples treating cells with 50, 200 and 500 µM ruthenium cylinder for two 
different treatment times of 1 and 24 hours; c) a positive control treating cells with 5 and 
50µM cisplatin; and d) negative controls for 1 and 24 hours. Following dye addition, the plate 
was read by plate readers.  
According to the presence of ChK1 phosphorylation in protein immunoblotting test 
demonstrates the DNA damaging or the stress on DNA strands, detection of the ChK1 
phosphorylation is the aim of this technique. It is worth noting that, the much higher 
concentration of cylinders than cisplatin were considered to have adequate ChK1 
phosphorylation levels following genotoxic stress in all samples to detect that well via 
sensitive films. 
 To measure the protein concentration in samples, a protein standard curve was generated 
considering the use of 10 µl standard protein, according to equation [3.2]: 
Starting protein concentration (µM) x volume of protein standard (µl) = amount of protein 
(µg) [3.2] 
After calculating the dilution factor, unknown samples were diluted twofold. 

























Average 0.865 0.256 0.406 0.32745 0.415 0.25 
5X µg 
protein/µl 
3.7 0.5 1.3 0.9 1.4 0.5 
For 20 
µg/gel 
5.4 38.8 22.4 15.3 14.7 41.3 
2X LB 5.4 38.8 22.4 15.3 14.7 41.3 
 
 
Table 3.3. Protein estimation in lysates of ruthenium cylinder samples, measuring loading 
















Average 0.49 0.28 0.38 0.23 0.25 0.22 
5X µg 
protein/µl 
0.3 0.5 0.4 1.2 0.6 1.8 
For 20 
µg/gel 
57.3 39.5 50.1 16.7 31.6 10.9 
2X LB 57.3 39.5 50.1 16.7 31.6 10.9 
 
Table 3.4. Protein estimation in lysates of negative and positive control samples, measuring 
loading samples per gel 
 






5 µM -24 
hrs 
Cisplatin 
5 µM -1 
hr 
Cisplatin 
50 µM -24 
hrs 
Cisplatin 
50 µM -1 
hr 
Average 0.3645 0.545 0.565 0.7855 0.265 0.6825 
5X µg 
protein/µl 
2.8 0.6 3.3 2.2 2 1.1 
For 20 
µg/gel 
7.2 33.5 6 9.3 18.2 9.8 





The above data was analysed to load 20 µg of unknown protein in each gel, and the samples 
were diluted by loading the buffer into prepared samples for gel electrophoresis. 
 
3.6.2 Protein gel electrophoresis 
Two different gels were made for each ruthenium cylinder and iron cylinder to assess the 
results. The goal was to separate proteins according to their size. [38] 
SDS, a kind of polyacrylamide gel, was used in this process to separate the proteins 
homogenised in lysate. Acrylamide was chosen to separate proteins depending on their size. 
The polymerisation process to make acrylamide gel was carried out when ammonium 
persulphate (APS), a polymerising agent, and N,N,N,N'-tetramethylenediamine (TEMED), a 




Fig. 3.20. Polyacrylamide protein polymerisation using bis-acrylamide for PAGE ammonium persulphate. 





Notably, nonpolar protein chains were transformed into linear polar chains with SDS gel. To 
this end, ionic SDS forms a bond with proteins to produce a homogeneously negative charge 
on the protein chain. All proteins bonded to SDS move through gel from a negatively charged 
cathode electrode to a positively charged anode electrode when a current is applied. 
Evidently, the sieving effect of the gel matrix impacts on protein migration through gel; 
lighter proteins move faster than massive ones through gel tunnels with different diameters. 
Therefore, smaller molecules are found at the bottom of the gel, and larger molecules are 
found at the top of the gel. [38,39] 
On the other hand, protein transformation to a linear shape is an influence of SDS which can 





Fig. 3.21. a) The effect of SDS on the conformation and charge of a protein. Taken from ref 41.; b) 
electrophoretic protein separation in polyacrylamide gel and protein migration. 
 
In this experiment, two different solutions were prepared to make the electrophoresis gel: 
running and stacking gel solutions. The difference in their pH, and the concentration of 
acrylamide, explain the tight bands formed during electrophoresis. The pH of 6.8 and lower 
concentration of acrylamide in staking gel allows proteins to be concentrated and some 
constricted bands to be formed at the beginning of electrophoresis, before entering the 
running gel. [42] 
To assess the test, the standard protein ladder was loaded into each gel as a reference of the 
molecular masses or sizes of proteins in a gel. Several proteins with known molecular masses 





one or more lanes of the gel. This type of prepared mixture of known proteins is called a 
ladder. There are different types of protein molecular weight (MW) markers used for different 
detection modes, which are categorised as unlabelled or pertained. [42] 
The ladder is a prepared mixture containing several proteins of known molecular masses is 
run alongside the test sample in one or more lanes of the gel. Several kinds of ready-to-use 
protein MW markers are available that are either unlabelled or prestained for different modes 
of detection.  
 
 
Fig. 3.22. The ladder used as a standard for protein separation. 
 
Ruthenium and iron cylinders in different concentrations (50, 200 and 500 µM) and times of 
treatment (1 and 24 hours) were loaded into different gels. Four separate gels were prepared 
for this test; two were loaded by ruthenium cylinder samples, and the other two by iron 
cylinder samples. Cisplatin in concentrations of 5 and 50 µM, and after 1 and 24 hours of 
treatments, were loaded as positive controls into gels. The gels were electrophoresed for 1.5 
hours and were checked during electrophoresis until completion. 
As mentioned above, proteins were moved into gels according to the difference in their size 
and their charge density. Therefore, the velocity of their movement can be calculated by the 







𝒗 = 𝑬𝒁/𝐟  
𝒗: 𝒗𝒆𝒍𝒐𝒄𝒊𝒕𝒚 𝒐𝒇 𝒕𝒉𝒆 𝒑𝒓𝒐𝒕𝒆𝒊𝒏 𝒐𝒓 𝑫𝑵𝑨 𝒊𝒏 𝒂𝒏 𝒆𝒍𝒆𝒄𝒕𝒓𝒊𝒄 𝒇𝒊𝒆𝒍𝒅 (𝒄𝒎. 𝒔𝒆𝒄−𝟏) 
E: electric field strength (volt.cm
-1
) 
Z: net charge on the protein 
f: frictional coefficient (depending on the mass and viscosity of the 
medium)  
 
Fig. 3.23. Protein migration and equation to measure its velocity in protein electrophoresis. Taken from ref 43. 
 
To detect and identify the proteins separated by gel electrophoresis, they were transferred to a 
membrane. This technique is called blotting. Notably, proteins can be re-natured by swoping 




The separated proteins were transferred to a membrane carrier to be specified and identified 
using the electrophoresis process. Gels were detached from the glasses and washed with 
transfer buffer in a small tank; they were then sandwiched with membranes in a special 
cassette in order to transfer the proteins from gel to membrane by electrophoresis. If the 
sequence of the gel and membrane arrangement in the cassette is not correctly placed, the 
transfer is not observed on the membrane. [35] 
The membrane is a solid support with high affinity to proteins chosen from the nitrocellulose 
membrane. This kind of membrane has a very good protein binding and maintains it for a long 
time. [35] 
Blotting was run for 1 hour at 100 V. Small proteins have a higher chance of passing through 
the membrane if the electrophoresis process is run for a longer time. Therefore, 1 hour is the 




The blotting visualisation of proteins in membranes was carried out using Ponceau Red, 
which is a kind of stain with low sensitivity. This reversible dye is a suitable choice to 
visualise whether or not the protein transfer on the membrane has occurred. The high 
solubility of Ponceau Red is the reason for its use at this step. It was then removed with water 




                        (a)                               (b) 
Fig. 3.24. a) The western blot cassette setup method. Taken from ref 44; b) correct orientation of cassette in 
the tank. Taken from ref 45. 
 
Protein imaging is the purpose of the western blotting test, which is done to detect specific 
proteins. High-quality images are necessary to analyse the proteins; therefore, to eliminate or 
reduce background noise in imaging, the unbound membrane sites should be blocked by 
washing in milk for 1 hour. Milk covers a thick layer at unbound membrane sites, and leaves 
tough sites of the membrane containing proteins. Ultimately, blocking the active sites of the 
membrane is necessary to take high quality images. In addition, this optimises antibody 
consumption through limiting the membrane sites. [35] 
The process of identifying proteins by their specific antibodies is called immunodetection. In 
this method, antibodies are used to recognise unblocked specific proteins on the membrane by 
Black site (cathode side) 





making bands with their proteins. The antibodies are chosen depending on the proteins 
targeted for investigation. [35] 
Depending on the antigen intended for detection and the related antibodies available, the 
primary antibody of a western blot is selected. Attention must be paid to choosing the 
appropriate primary antibody for western blotting, because not all primary antibodies can be 
used for this purpose. Primary antibodies are frequently applied first and then recognised by a 
secondary antibody which is conjugated with colour, radioactivity or an enzyme, as well as 
biotin-conjugated antibodies. [46] 
There are two different methods of protein identification: direct and indirect immunodetection 
methods. They have their own advantages and disadvantages for detection of the target 
proteins. The labelled primary antibody is used as a direct method, while the unlabelled 
primary antibody flowed by a labelled secondary antibody is used as an indirect detection 
method for proteins. [46] 
Anticancer agents target DNA as the most effective part of a cell to treat cancers. However, 
they can also affect the nature of DNA in different ways. For example, cisplatin induces DNA 
damage and causes cell death, and gemcitabine and etoposide inhibit DNA duplication. 
Because iron and ruthenium cylinders are categorised as DNA replication fork inhibitors, the 
antibodies activated during this process should be considered as a checkpoint for evidence of 
their lack of genotoxicity anticancer activity. 
Apical protein kinase (ATR) and its downstream target kinase (ChK1) have a significant 
effect on DNA, damaging checkpoint control, and on tumour abolition. Any stress on the 
DNA replication process, such as interrupting DNA duplication, activates the ATR-ChK1 
pathway to delay cell cycle progression, and keeps the replication fork feasible. DNA 
duplication can continue after correction of the primary damage. Moreover, phosphorylation 
of ChK1 by ATR, which results from DNA damage, triggers its release from the chromatin-
enriched fraction into soluble nuclear, cytoplasmic and centrosome compartments, where it 
coordinates the activation of the cell cycle arrest or repair function, as well as being degraded 
to terminate the activated checkpoint. [47] ChK1 phosphorylation represents different 
functions that work continuously together. Interceding the DNA replication checkpoint is 
known as ChK1 phosphorylation, which is a crucial duty to keep the cell alive and can occur 
during phosphorylation at Ser-317. This is essential to activate the process of phosphorylation 




phosphorylation in whole cell lysate is the sign of cylinder activity as an anticancer which 
drives cells to death by blocking DNA synthesis in U2OS cells. Therefore, ChK1 and ChK1 
phosphorylation antibodies were used to represent the disruption of DNA replication in 
cancerous cells. 
The next step is to apply primary antibodies to bind with targeted proteins. To this end, one of 
the membranes of ruthenium and iron cylinders were placed in ChK1 (mouse, G-4, lot: 
A1713, from Santacruz Biotechnology) antibody, which was diluted as 1 µl in 10 ml of milk 
(labelled as ChK1). Two other membranes were placed in phospho-ChK1 (rabbit, Ser-345, 
CAS: 234 1 L, from cell signalling), diluted as 10 µl in 10 ml of BSA (labelled as ChK1-P). 
All of the solutions were stored in a cold room and agitated overnight. These two antibodies 
marked the targeted IgG2a protein and ser-345 phosphorylation in lysate cells. After 24 hours, 
membranes were washed with TBS several times to completely remove the primary 
antibodies. 
The secondary antibodies were added to provide double coded proteins, in order to produce 
better images. The membrane labelled ChK1 was placed in the solution of anti-mouse diluted 
in block (16 µl in 50 ml of block), and the membrane labelled P-ChK1 was placed in an anti-
rabbit solution (50 µl in 50 ml block) and kept at room temperature with agitation. 
Membranes were washed with TBS several times and were then detected by ECL detection 
reagents. Chemiluminescence was chosen as an adequate detection technique to mark the 
targeted proteins in the laboratory. Two-component chemiluminescent substrates for 
horseradish peroxidase (HRP) include a stable peroxide solution and a modified luminal 
solution. The same amounts of each HRP substrate peroxide solution (WBK LO500 
Millipore) and HRP substrate luminal reagent (WBK SØ500 Millipore) were added to each of 
the mouse and rabbit trays as a working solution, and stored for 3–5 mins. HRP was 
conjugated to antibodies and light was generated by the chemical reaction, and subsequently 
detected with sensitive film. Films were prepared in a dark room and analysed in comparison 
with the membrane ladder. 
The process was repeated on the same lysate samples three times to obtain the best repeatable 
and reliable results for analysis. The results were also compared to each other. 
Because the western blotting technique is a highly sensitive process in response to the types of 




produce a strong signal from the targeted proteins, the repeated tests did not show the same 
results. 
Since the inhibition of the DNA replication fork with ruthenium and iron cylinders was one of 
the goals of this experiment, the cell cycle checkpoint kinase ChK1 is important for 
consideration. The DDR or DNA damage response was activated when any replication stress 
or DNA damage happened in cells. A direct response to stalled replication fork signals is 
ChK1 as a kinase checkpoint, which is phosphorylated on ser345 by ATR (ataxia 
telangiectasia and Rad3-related protein). Consequently, the separated proteins extracted from 
lysate were exposed to ChK1 of mouse and phosphorylation ChK1 (ser345) of rabbit. In this 
test, lysates from cells of treated samples of 50, 200 and 500 µM of ruthenium and iron 
cylinders and 50 µM cisplatin as a positive control for 1 and 24 hours were verified. It is 
















Fig. 3.25. Detection of HRP conjugated secondary antibodies (ChK1 mouse & P-ChK1 rabbit) for both 
ruthenium and iron cylinder-treated samples (Test 1). 
 
As shown in Figure 3.25, the levels of ChK1 and phosphorylation ChK1 is considered to be a 





of both cylinders (iron and ruthenium) in all concentrations and exposure times, in addition to 
both positive (cisplatin 50 µM for 1 and 24 hours) control. Samples exposed to the ruthenium 
cylinder for a longer time (24 hours) showed higher levels of ChK1 in their lysates. Moreover, 
ChK1 in iron cylinder samples showed the same result except for the samples treated with 
cisplatin after 24 hours and 50 µM iron cylinder after 1 hour, which did not show ChK1 in 
their lysates. This could be related to the initial level of protein concentration in their lysates. 
In contrast, ChK1 phosphorylation on serine 345 as a sign of stalling the replication fork was 
not observed in any ruthenium and iron cylinder samples. This could have happened due to 
the expiration of one of the antibodies used in this process. Alternatively, it may suggest that 
neither cylinder inhibited the DNA replication fork. 
The test was repeated on the same samples by applying a new secondary P-ChK1 antibody 
(anti-rabbit) to reassess the process and results. This repeat produced showed contradictory 
results compared to test 1. The ChK1 protein was not detected in lysates, but ChK1 
phosphorylation was detected only in samples treated with cisplatin 50 and 5 µM and iron 
cylinder 200 and 500 µM after 24 hours. One explanation for the lack of ChK1 protein in film 
after detection could be the problem of the primary antibody (Fig. 3.26). Since the ChK1 
checkpoint kinase is activated by any minor damage or stress to DNA replication (known as 
DNA damage response or DDA), it should be identified in all lysates or at least in the 
cisplatin samples. Nonetheless, none of the samples responded to ChK1 antibody, which 
could be interpreted as the consequence of the antibody defect. The detection of ChK1 
phosphorylation in some samples revealed damage on the replication fork in cisplatin 
samples, and stress on the replication fork in iron cylinder samples both in the highly-






The process was repeated again using a fresh primary ChK1 antibody on the same lysates 
(that were kept frozen at -80 ̊C) to evaluate the result of the iron cylinder effect on the 
replication fork, by the detection of ChK1 phosphorylation protein. Undesirably, the results 
were similar to those of test 1, and P-ChK1 was not detected in either iron or ruthenium 
cylinder samples. The level of ChK1 protein in samples as a parameter of DNA stress was 
high in all samples of iron cylinder. Ruthenium cylinder activated the DDH network in 50, 
200 and 500 µM treatments after 24 hours, with a marked difference in the level of ChK1 
protein in samples treated with cisplatin. 
 
 
Fig. 3.26. Detection of HRP conjugated secondary antibodies (ChK1 mouse & P-ChK1 rabbit) for both 







Fig. 3.27. Detection of HRP conjugated secondary antibodies (ChK1 mouse & P-ChK1 rabbit) for both 
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This thesis investigated the properties of triple-stranded iron(II) and ruthenium(II) helical 
cylinders and their effects on the osteosarcoma U2OS cell line as anticancer agents. It 
attempted to answer the following fundamental questions: 
i. How do the cylinders enter the cell, and where do they localise in the cell?  
ii. How do they interact with key biomolecules in the cell, such as genomic DNA, 
and what are the downstream cellular effects of these interactions? 
iii. What are their effects on the cell in vitro? 
The ICP-MS results demonstrate the cellular uptake of the triple helix ruthenium(II) cylinder 
as a noncovalent DNA binder anticancer drug in different parts of U2OS cells. These results 
indicate that only 26% of the ruthenium cylinder is absorbed intracellularly over the course of 
four hours. Consequently, a large amount of the ruthenium cylinder is trapped in the 
membrane and is not uptaken by U2OS cells. The percentage of ruthenium cylinder cellular 
uptake in the nucleus (16%) is approximately twice that uptaken in the cytoplasm (9.68%), 
thus illustrating the greater preference for binding to genomic DNA of the cylinder on cells by 
gene interactions. Future work should investigate iron cylinder cellular uptake with and 
localisation in U2OS cells. A subsequent comparison of the iron and ruthenium cylinder 
results, and examination of the percentage of iron cylinder intake in the nucleus.  
Studying the effects of both cylinders on U2OS cells in vitro revealed that the toxicity of the 
ruthenium cylinder is greater than that of the iron cylinder against U2OS cells; their IC50 
values are 18 µM and 26 µM, respectively. Although both cylinders demonstrated strong 
toxicity in the treatments, the water solution of cisplatin did not show a high toxicity against 
the studied cancer cells. Furthermore, the genotoxicity studies of cylinders on DNA as an 
important genomic biomolecule demonstrate a low level of DNA damage in U2OS cells after 
4 and 24 hours of treating. It is important to note that these results are valuable for smart 
cancer therapy. In future, iron and ruthenium cylinder cytotoxicity against U2OS cells should 
be investigated on two different timescales: 1) after 1, 2, 4, 8 and 12 hours; and 2) after 1, 2 
and 3 days. These results could help in understanding the toxicity effects of these complexes 
over time in the studied cells. In addition, this information could help to find the minimum 
time required for the high toxicity impact of complexes in the studied cells.  
Furthermore, this research needs to be extended by examining the reduction in cell growth 




using the crystal violet assay technique. Comparing the growth curves of U2OS cells 
unexposed and exposed to cylinders after five days would provide an invaluable set of 
information about the effects of the complexes on cells. Moreover, CellTrace Violet could be 
used to track cell proliferation over time by fluorescent dye dilution or flow cytometry. 
Microscopy imaging and western blot techniques were used in this study to investigate the 
modes of interaction of ruthenium and iron cylinders with the DNA of U2OS cells. Previous 
studies have demonstrated that iron and ruthenium cylinders are active against many cancer 
cells because they form a noncovalent bond with the major groove of DNA. In this way, cell 
apoptosis occurs as a result of blocking the major groove, and subsequently the replication 
process. Similarities in the particular size and structural shape of cylinders are reasons to 
expect the same activity under the same conditions. 
In previous studies, microscopy imaging using the Hoechst stain as a DNA groove binder has 
demonstrated Hoechst bleaching with cylinders as a sign of Hoechst replacement on the 
groove of DNA. Despite these outcomes, the replacement of Hoechst is not seen in the iron or 
ruthenium treatment samples of U2OS cells in this study. In addition, the fluorescent ability 
of the ruthenium cylinder helped to detect this complex inside cells, particularly in the 
nucleus, by fixed-cell microscopy. These results indicate that the cylinders cross the cell 
membrane, and the ruthenium cylinder is then detected inside the nucleus. In this way, the 
cellular uptake of the cylinders in U2OS cells is demonstrated here. However, there is no 
evidence for interaction between the cylinders and DNA major grooves. 
Inhibition of the DNA replication fork with both iron and ruthenium cylinders was a principal 
goal of this work on U2OS cells. Since any stress on the DNA replication process, such as the 
interruption of DNA duplication, activates the ATR-ChK1 pathway to keep the replication 
fork feasible, the existence of checkpoint kinase in cell lysates signals the effects of the drug 
on the DNA replication fork. The western blot represents various uncertain results in samples 
with both iron and ruthenium cylinders in samples after several attempts. The ChK1 protein 
was detected in all samples treated with the iron cylinder and cisplatin after 1 and 24 hours. 
Meanwhile, this protein could only be detected in some samples treated by ruthenium 
cylinders after 24 hours. The detection of P-ChK1 as a sign of DNA replication fork 
inhibition by cylinders was not proved, although it was observed once in samples treated with 
iron cylinders. In contrast to samples treated with ruthenium cylinders, these results prove the 




treated with 200 µM and 500 µM of the cylinder, also it should be noted that those 
concentrations of cylinders are very high. Accordingly, concerning the similarity in the sizes 
and shapes of iron and ruthenium cylinders, the results of the western blot do not prove the 
same activity between iron and ruthenium cylinders in their interaction with the DNA 
replication fork in U2OS cells. These results did not enable the process to be followed by 
examination of the possibility of cylinder interaction with the DNA replication fork by DNA 
fibre analysis. This work clearly needs to be repeated with fresh primary and secondary 
antibodies in new cell lysates treated with iron and ruthenium cylinders. Positive results in 
order to detect the P-ChK1 protein in cell lysates are required to further investigate the 
interaction between cylinders and the DNA replication fork, by fibre analysis.  
In conclusion, the thesis work represents the high cytotoxicity and non-genotoxicity effect of 
ruthenium cylinder and iron cylinder in U2OS cells. Whereas the mechanism of action of both 
cylinders in U2OS cells especially their interaction with DNA duplex were not clarified. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 





